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Abstract 
Feline corononavirus (FCoV) infection is ubiquitous in domestic cat populations 
worldwide and is usually associated with subclinical or mild enteritis. However, in some 
cats infection may result in the development of a fatal progressive disease called feline 
infectious peritonitis (FIP). FIP is considered to be the major cause of infectious-related 
death in pet cats. Currently, there is no protective vaccine or curative treatment to this 
highly fatal disease. In this study, we evaluated the ability of small interfering RNAs 
(siRNAs) to inhibit the in vitro viral replication and gene expression of FCoV as a potential 
treatment for FIP. 
Five synthetic siRNAs were designed to target different regions of the FCoV 
genome. The siRNAs were tested individually and in various combinations in vitro for their 
antiviral effects against 2 strains of FCoV (feline infectious peritonitis virus WSU 79-1146 
and feline enteric coronavirus WSU 79-1683). Tested combinations targeted the FCoV 
leader and 3′ untranslated region; FCoV leader region and nucleocapsid gene; and FCoV 
leader, 3′ untranslated region, and nucleocapsid gene. For each test condition, 
assessments included relative quantification of the inhibition of intracellular viral genomic 
RNA synthesis by means of real-time, reverse-transcription Polymerase chain reaction 
(PCR) analysis; flow cytometric evaluation of the reduction of viral protein expression in 
infected cells; and assessment of virus replication inhibition via titration of extracellular 
virus with a 50% tissue culture infective dose (TCID50) assay.   
The 5 siRNAs had variable inhibitory effects on FCoV when used singly. 
Combinations of siRNAs that targeted different regions of the viral genome resulted in 
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more effective viral inhibition than did individual siRNAs that targeted a single gene. The 
tested siRNA combinations resulted in approximately 95% reduction in viral replication 
(based on virus titration results), compared with findings in negative control non-targeting 
siRNA-treated FCoV-infected cells. This study shows that FCoV replication can be 
specifically inhibited by siRNAs that target coding and noncoding regions of the viral 
genome, suggesting a potential therapeutic application of RNA interference in treatment 
of feline infectious peritonitis. 
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Introduction 
Feline coronavirus (FCoV) is a common virus in domestic cats usually associated 
with subclinical infection or mild enteritis. However, some FCoV-infected cats develop 
feline infectious peritonitis (FIP), a progressive and fatal disease that accounts for the 
majority of infectious disease-related deaths in pet cats [1].   FIP may manifest acutely 
with peritoneal and/or pleural effusion or may have a more protracted course with 
pyogranulomatous infiltration of multiple tissues. Both manifestations invariably end in 
death. The pathogenesis of FIP involves a mutant FCoV that can replicate efficiently in 
monocytes and macrophages leading to dysregulation of host cell-mediated immunity, 
allowing the virus to replicate unchecked to a high titer [2]. Systemic viral replication 
appears to play a critical role in FIP pathogenesis. Further, Contributing to the 
pathogenesis of FIP are cytokines and inflammatory mediators released from infected 
macrophages, other inflammatory cells that infiltrate tissue, as well as antigen-antibody 
complexes and complement activation [3].  
To date there is no specific treatment for this fatal disease. In this work, we 
describe the use of individual siRNAs and/or siRNA combinations as a means of inhibiting 
FCoV replication. Using siRNAs is a novel antiviral strategy that specifically targets viral 
mRNA and genomic RNA for degradation by endogenous cellular enzymes.[4] This 
technology has been employed successfully for viral diseases such as viral hepatitis and 
severe acute respiratory syndrome (SARS) both in vitro and in ex-vivo [5].  
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Study hypothesis: 
 Inhibition of FCoV translation and replication using siRNAs (singly and in combinations) 
that specifically target coding and noncoding regions of the viral genome can help in 
treating FIP disease. 
Study objectives: 
1. Design feline coronavirus-specific siRNAs that can hybridize to viral coding or 
noncoding regulatory regions of the genome. 
2. Optimize transfection condition. 
3. Screen synthesized siRNAs individually and in different combinations for their 
effectiveness in inhibiting FCoV replication in cell culture as assessed by: a) 
relative quantification of the inhibition of intracellular viral genomic RNA synthesis 
by means of real-time, reverse-transcription PCR (RT-PCR) analysis; b) flow 
cytometric evaluation of the reduction of viral protein expression in infected cells; 
and c) assessment of virus replication inhibition via titration of extracellular virus 
with a TCID50 infectivity assay.   
Feline Coronavirus Review of Literature 
Feline coronavirus 
Feline coronavirus infection (FCoV) is ubiquitous in domestic cats and particularly 
common in multi-cat settings, where cats are shedding the virus in feces and sharing litter 
boxes. FCoV infection may be asymptomatic or may result in mild enteritis. In this case, 
the causative agent is referred as feline enteric coronavirus (FECV). In a relatively small 
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percentage of cats, a fatal, multisystemic, immune-mediated disease develops and is 
known as feline infectious peritonitis (FIP).  In this case, the causative agent is referred 
as feline infectious peritonitis virus (FIPV) [6]. It is believed that cats most likely acquire 
FIPV by mutation of an endogenous FECV [7, 8] or rarely through excreted virus from 
other FIPV infected cat [9]. 
Classification and virion properties 
 FCoV is a member of the family Coronaviridae, order Nidovirales. The family 
Coronaviridae comprises two subfamilies, Coronavirinae and Torovirinae. Based on the 
serological and the genetic properties, the Coronavirinae subfamily has been divided into 
three new genera, Alphacoronavirus, Betacoronavirus, and Gammacoronavirus formerly 
named group 1, 2 and 3, respectively [10]. Further, each genus is divided into different 
species according to the identity of the sequence of the replicase domains of the 
polyprotein 1ab.The FCoV, porcine transmissible gastroenteritis virus (TGEV) and canine 
coronavirus (CCoV) show more than 96% homology within these domains and have been 
grouped in the same species, alphacoronavirus 1, within the Alphacoronavirus genus 
[11].  
FCoV is an enveloped virus with a large single-stranded, positive sense capped 
and polyadenylated RNA genome of about 30 kilobases (Kb). The FCoV genome 
contains 11 putative open reading frames (ORFs). These ORFs encode viral non-
structural replicase proteins; structural proteins (spike, envelope, membrane, and 
nucleocapsid proteins); and 5 accessory ORFs of unknown function. Based on sequence 
analysis of strain FIPV WSU-79/1146, the genome 5' untranslated region (UTR) consists 
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of about 310 nucleotides (nt) including the leader sequence (nt 1 to 92) that play an 
important role in the viral mRNA synthesis. The viral 3' UTR contains a putative bulged 
stem loop and pseudoknot followed by the poly (A) tail and is known to also play an 
important role in regulating the virus replication [12]. 
Viral proteins 
Viral non-structural proteins 
Approximately two-thirds of the viral genome encodes the replicase gene 
comprising ORFs 1a and 1b. Translation of the coronavirus replicase gene gives rise to 
the primary translation products polyprotein 1a (pp1a) and polyprotein 1 ab (pp1ab), 
which are processed by virus-encoded protease to generate 16 functional subunits of the 
replication/transcription machinery. Among these subunits are the RNA-dependent RNA 
polymerase and the helicase. ORF1 also encodes the viral proteases needed for this 
proteolytic process. The replicase products assemble into replication-transcription 
complexes (RTC) which are embedded in cellular membranes to make double-membrane 
vesicles that serve as viral RNA synthesis sites [12]. 
Viral structural proteins 
There are four ORFs that encods the viral structural proteins; spike (S), envelope 
(E), membrane (M), and nucleocapsid (N) proteins. Trimers of the (S) protein form the 
characteristic peplomers that protrude from the virion membrane. The S protein is 
responsible for viral attachment to specific host cell receptors and for cell-to-cell fusion 
[11]. The E protein has ion channel activity and plays an important role in viral envelope 
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assembly [13].  The M protein, the most abundant structural component, is a type III 
glycoprotein consisting of a short amino-terminal ectodomain, a triple spanning 
transmembrane domain, and a carboxyl-terminal inner domain [14]. The interaction 
between the M and S proteins facilitates the encapsulation of the S protein into new virion. 
The N protein encloses the viral RNA genome and forms the ribonucleocapsid. Also the 
N protein plays an important role in viral replication and is part of the RTC. The N protein 
has also been shown to localize to the nucleoli to exert an impact on the cell cycle 
progression to ensure maximal translation of viral mRNAs. In addition, the N protein plays 
an important role in circumventing the innate immune response because it is reported to 
be an interferon (IFN) antagonist [15]. 
Viral accessory proteins 
 The ORFs 3 and 7 encode the 5 accessory proteins; 3abc and 7ab. The function 
of these proteins is still unknown. They are not required for infection because a mutated 
virus in which ORF 3 and 7 are deleted can still replicate in vitro as well as the wild type 
strain. ORF7b encodes a secretory, hydrophilic protein of 22 kDa that has been 
suggested to serves as an immune modulator. The ORF 7a encoded protein is reported 
to be an IFN antagonist and protects the virus from the antiviral state induced by IFN, but 
it needs the presence of ORF3 encoded proteins to exert its antagonistic function [16]. 
Virus replication 
  Like other coronaviruses, FCoV uses a discontinuous transcription mechanism 
to synthesize both full-length and subgenomic (sg) negative-strand RNAs, which then 
function as templates for synthesis of full-length genomic RNA and positive-strand 
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sgRNAs, respectively.  Both viral genome and sgRNAs share a common 5' leader 
sequence and a common 3' UTR [17].  
The replication cycle of the coronavirus starts by attachment of the S protein to the 
host cell receptor, followed by cell pentration via endocytosis. The low pH in the cytoplasm 
enables the release of the viral genome into the cytoplasm. In the infected cell, 
coronavirus gene expression starts with the translation of the replicase gene. The 
synthesized 16 replicase-transcriptase proteins assemble into the RTC together with 
other viral proteins (such as the N protein) and cellular proteins to mediate the replication 
of the genomic RNA and transcription of a nested set of (sg) mRNAs [18]. The RNA 
dependent RNA polymerase transcribes the genome to its complementary full length 
negative-stranded RNA, which serves as a template for the viral progeny genomes.  
For viral genome transcription, the viral polymerases transcribe a negative sense 
sgRNA for each gene.  The elongation of the synthesized negative-stranded sgRNA 
continues until the first transcription regulatory sequence (TRS) is encountered. TRS is a 
short motif (about 10 nucleotides) that can be found in the genome at the 3’ end of the 
leader sequence and in front of each ORF and is very important to identify each gene 
boundary. Then the RTC will either disregard the TRS motif and continue the elongation 
or will stop synthesis of the minus strand and relocate to the 5’ end of the genome in order 
to complete its synthesis and to copy the leader sequence located at the 5’ most end of 
the viral genome. The leader sequence is then fused with the body of the synthesized 
sgRNA. This completed sg minus-strand RNA will then serve as a template for the positive 
stranded mRNA synthesis. The incorporation of the leader sequence in each sgRNA is 
important for signaling for the ribosome to translate the encoded protein [18]. After the 
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synthesis of the viral proteins and progeny viral genome, the N proteins bind to the newly 
replicated genomic RNA strand to form the helical ribonucleocapsid. Then the M protein 
and the E proteins are integrated into the membrane of the endoplasmic reticulum and 
guide the virus assembly [14]. Subsequently the virus buds and gains its envelope from 
the endoplasmic reticulum membrane. Finally these viral progeny are transported by 
Golgi vesicles to the cell membrane and released via exocytosis.  
Viral serotypes and biotypes 
FCoV is classified into 2 main serotypes based on the sequence of the S protein; 
FCoV serotype I and FCoV serotype II. FCoV serotype I is highly prevalent in the field 
causing approximately 80% of all infections. FCoV serotype II is less prevalent and arose 
from a recombination event between a type I FCoV and CCoV that resulted in the 
replacement of the FCoV spike gene with the CCoV spike gene [19]. The majority of the 
research on FCoV has been conducted on serotype II, because it can propagate easily 
in cell culture and is, therefore, easy to work with in the laboratory.  
Each serotype is further subdivided according to its pathogenicity into two 
biotypes: the avirulent FECV and the virulent FIPV.  FECV is ubiquitous among cats and 
causes mild to often subclinical enteritis. In contrast, FIPV leads to a devastating, fatal, 
systemic disease that is marked by severe pyogranulomatous inflammation. Neither 
serotype is more commonly associated with FIP than the other, nor is the virus of FIP 
antigenically distinct from the avirulent FECV [6]. Furthermore, there is no consistent 
genetic difference that defines the two biotypes, though mutation of an avirulent FECV is 
thought to give rise to FIP in an individual. The differences among isolates from the same 
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group of cats are small, rarely more than 1-2%, but can be up to 20% among isolates 
from different geographic regions [5]. Currently the marked difference between the two 
biotypes is the replication site. The primary replication site of FECV is localized in the 
lower portion of the intestinal tract, whereas the FIPV main replication site is the 
macrophages and monocytes. Thus FIPV and FECV can only be distinguished by the 
clinical disease they cause in cats. 
Feline infectious peritonitis (FIP) 
Feline infectious peritonitis (FIP) is a fatal, progressive disease of cats that 
responds poorly to treatment. This disease was first documented in the late 1950s by 
necropsy records at the Angell Memorial Animal Hospital, Boston MA [20]. Since then, 
there has been a steady increase in the incidence of the disease and this disease now 
accounts for the majority of infectious disease-related deaths in pet cats. In 1963 FIP was 
officially described as an important cats’ disease, but the causative agent of FIP was not 
known to be viral until 1966 [21]. Then in 1972, it was known that the virus can cause two 
different forms of the disease identified as wet and dry forms [22].  In 1978 the antigenic 
relationship of FIPV to canine, porcine, and human Coronaviruses was determined and 
the notion that FIPV is a mutant form of FECV was first verified in 1998 [8]. 
Clinical and pathological features  
Early in the disease, the FIPV infected cat develops nonspecific symptoms such 
as loss of appetite, weight loss, depression, rough hair coat, fluctuating antibiotic resistant 
fever and increased susceptibility to secondary infections. Once symptoms develop, 
usually there is an increase in the severity of the disease over the course of several 
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weeks, ending in death. Whereas the more specific signs of the disease depend on the 
form of the disease. There are two major forms of FIP, an effusive or wet form, and a non-
effusive, parenchymatous, or dry form [6].  
The effusive form of FIP is the most common form that can occur within 4-6 weeks 
of infection and is characterized by effusive inflammation of the serosal membrane and 
accumulation of fluid in the peritoneal cavity, or less commonly in the pleural cavity [23].  
In some cases excessive pleural effusion can lead to respiratory distress and dyspnea. 
The peritoneal and pleural fluid is secondary to vasculitis and leakage of fluid from the 
vasculature. The fluid is usually a yellow-tinged, slight to moderately cloudy 
pyogranulomatous inflammatory exudate with diffuse granular fibrinous exudation 
covering serosal surfaces or floating in the effusion. Microscopically the pyogranulomas 
are made up of central aggregates of viral infected macrophages around small venules 
and surrounded by a rich inflammatory exudate containing mainly neutrophils and 
macrophages with a scattering of plasma cells and T-lymphocytes. Occasionally the wet 
form is associated with eye and/or nervous tissue lesions [6]. 
The dry, parenchymatous, or non-effusive FIP form is the chronic form of the 
disease that can incubate for months to years and is characterized by pyogranulomatous 
lesions of parenchymatous organs such as the kidneys, mesenteric lymph nodes, bowel 
wall, liver, central nervous system (CNS) and the eyes. The pyogranulomas of the dry 
FIP consist of foci of macrophages around vessels surrounded by dense infiltrates of 
lymphocytes (mainly B-cells) and plasma cells that extend into surrounding tissues, as 
seen in classical granulomas [6].  The clinical signs associated with the dry form depend 
on which organ is affected. If the kidneys are affected, they become enlarged due to 
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pyogranulomatous lesions in the cortex. The infected cat may exhibit polyuria, polydypsia, 
vomiting, proteinuria, and azotemia. The liver may have focal necrotizing 
pyogranulomatous inflammation involving hepatic capsule and adjacent hepatic 
parenchyma and affected animals may have increased liver enzymes, including ALT, 
GGT, alkaline phosphatase, or hyperbilirubinemia [24]. The brain and spinal cord may 
have meningoencephalitis and myelitis, with vasculitis. Thus the cats may exhibit 
seizures, abnormal behavior, central vestibular signs, ataxia, hyperesthesia, and 
abnormal postural reactions [25]. The eyes may have bilateral anterior uveitis due to 
lymphatic and plasmacytic infiltration that is manifested by swelling and discoloration of 
the iris, Keratic precipitates on the caudal aspect of the cornea may occur due to 
accumulations of fibrin, macrophages, and other inflammatory cells that have exuded 
from the inflamed uveal tract [26]. Lungs may have granulomatous pleuritis and 
pneumonia.  
Lymphoid lesions are common in effusive and non-effusive FIP [24,6]. Splenic 
enlargement may be due to histiocytic and plasmacytic infiltration of the red pulp, 
hyperplasia of lymphoid elements in the white pulp, necrotizing splenitis with fibrin 
deposition and polymorphonuclear cell infiltrates (more common in wet FIP), or by more 
organized pyogranulomatous reactions(more common in dry FIP). Lymph node 
enlargement is usually limited to thoracic and abdominal nodes with lesions resembling 
those described for the spleen. 
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FIP pathogenesis 
  FCoV like other RNA viruses has a high mutation rate because viral polymerases lack 
proof-reading ability. Thus, several genetic forms of the virus may co-exist in the same 
animal at the same time. Most of these mutations have very little effect on the behavior 
of the virus. However, certain mutations that affects the function of certain genes may 
have a marked effect on the biological behavior of the virus and may lead to change in 
the viral tropism and/or virulence. Thus, the pathogenesis of FIP is believed to be caused 
by mutant FECV that gain the ability to replicate efficiently in monocytes/macrophages 
and lead to dysregulation of host cell-mediated immunity, allowing the virus to replicate 
systemically  unchecked to a high titer. Speculation on the genomic locale of this mutation 
has involved the genes encoding the viral structural and nonstructural proteins. The spike 
gene was one of the viral structural genes that was implicated in the mutation of the FECV 
to FIP [27, 28]. Recently, one study looked at mutations in the S protein domain referred 
to as the S1/S2 domain that is cleaved by the viral protease to produce a functional S 
protein. This study found mutations in the S1/S2 motif in FIPV, whereas, many but not all 
of the FECV have a conserved motif. Though, these mutations influence the efficiency of 
the protease to cleave the precursor S protein, their exact role in the viral pathogenesis 
is not established. Some mutations in the motif were discovered to increased protease 
cleavage efficiency, other mutations decreased the efficiency, and in some cases the 
mutation had no effect on the cleavage efficiency [29]. Other researchers have proposed 
that mutation of viral accessory genes might be associated with variation in virulence 
observed in FCoV biotypes. Studies showed that the ORF 7 gene is often mutated in 
FECV, while conserved in FIPV [8]. Thus, the viral ORF 7 accessory gene was proposed 
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to be a virulence marker. However, mutation of this gene was identified later in the 
genomes of both FECV and FIPV, implying that the mutation/deletion in this gene is not 
correlated with FIP pathogenicity [30]. Further, several FIPVs that have been shown to 
display decreased virulence with tissue culture passaging have maintained intact, non-
mutated 7b genes,  confirming that mutation in ORF 7 gene is not associated with FIPV 
virulence.  
Another accessory gene that was considered to be involved in FIPV pathogenesis 
was the 3c gene [31].  ORF3c is intact in all strains of FECV. Thus, it was proposed that 
the 3c is essential for the replication of FECV in the gut and mutation in this gene may 
lead to change in the viral tropism and enhance the viral replication in the monocytes and 
macrophages.  However, as some FIPV strains (about 30%) seem to have intact ORF3c 
[6, 31], it is likely that 3c mutations are not the only cause of FIP pathogenesis and 
combinations of mutations might be required for FIP to develop. Despite intensive 
research in this area, there is no consistent genetic difference identified that defines 
virulent versus avirulent biotypes. At least one study found 100% homology between the 
structural and accessory genes of enteric and non-enteric (liver) viral genomes from a cat 
with FIP [9]. A distinguishing factor appears to be quantitative differences in viral RNA 
levels in the blood of cats with and without FIP [32].  Rising amounts of viral RNA in the 
blood seen in the end-stage of FIP may indicate that loss of immune control leads to 
enhanced viral replication and disease progression. Thus, the increased viral replicative 
capacity seems to be an important element of FIP pathogenesis. 
Another crucial element of FIP development is the lack of an effective immune 
response. Specifically cell-mediated immune response (CMI) is essential for protection 
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against FIP. Cats with a strong CMI will survive, while cats with poor CMI will develop 
FIP.  Lymphocyte depletion has been observed in affected cats, despite lack of viral 
infection of these cells. The cause of the lymphocyte depletion is unknown, but the release 
of inflammatory mediators and cytokines from viral infected cell has been suggested to 
play a critical role in this depletion [2]. Cytotoxic T lymphocytes (TC), T helper (TH), 
regulatory T (Treg) as well as natural killer (NK) cells are markedly depleted in the blood 
of cats with FIP[2, 33]. As a consequence the capacity of the innate CMI mediated by the 
NK as well as the adaptive CMI mediated by the TC to destroy the infected macrophages 
and to clear the virus is reduced. Further the depletion of the Treg cells enhances the 
immune mediated pathology associated with the FIP infection. While cell-mediated 
immunity is compromised, the humoral response is exaggerated. The virus-specific 
antibodies bind to the virus in circulation, or in tissue sites, precipitating cellular damage. 
As a consequence, the lesions associated with FIP are due primarily to immune-mediated 
destruction. Contributing to the pathogenesis of FIP are cytokines and inflammatory 
mediators released from infected monocytes/macrophages, other inflammatory cells that 
infiltrate tissues, as well as antigen-antibody complexes and complement activation [3]. 
Also leukocytes from FIP cats were found to have increased expression of adhesion 
molecules that enhance their endothelial adherence ability and subsequent migration to 
the surrounding tissue to add to the pyogranulomatus lesion associated with FIP. Further, 
vascular endothelial growth factor (VEGF), produced by FIPV infected monocytes and 
macrophages, induces vascular permeability and may be an important contributor to 
abdominal and thoracic effusions in cats with wet FIP [34]. 
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In addition to virus specific factors, genetic and environmental factors may have a 
role in FIP. The ability of an animal to produce an effective immune response depends in 
part on its genetic composition. Studies have shown a genetic predisposition to disease 
occurrence. Certain breeds, including Bengals, Birmans, and Himalayans, are more likely 
to develop FIP. However, the exact host genetic factors that may be involved remain to 
be identified. Studies have shown that the monocytes from different cats do not have the 
same susceptibility to FCoV infection, suggesting a genetic role in the susceptibility of 
monocytes to FCoV infection. Environmental factors including; stressors, such as 
crowded housing, trauma, pregnancy, surgery or other infections have been assumed to 
be associated with FIP development. Stress can depress the host immune system 
increasing the likelihood that FIPV will establish itself in the body or may allow an FIPV 
that is being successfully contained to become active. Disease caused by feline 
herpesvirus and other common upper respiratory pathogens are good indicators of cattery 
or shelter stresses. If a cattery or shelter is having a lot of problems with these upper 
respiratory infections, it is likely that they will also have problems with FIP.  Therefore, it 
is important to minimize the exposure of cats to stress especially FCoV seropositive ones.  
 FIP treatment and control 
To date, treatment of FIP has been ineffective, with affected cats progressing 
inevitably to death. Because of the immune-mediated component of the disease, 
therapies directed at enhancing the CMI response and/or suppressing the humoral 
response have been tried with little or no success. For the enhancement of the host 
immune response, human and feline recombinant IFNs have been tried. Although IFN 
showed inhibition of FCoV replication in vitro, in vivo studies have shown no effect on 
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survival time or quality of life [35]. Recently, polyprenyl, a new therapeutic that is 
postulated to enhance T lymphocyte activity, has been used with some success in dry 
forms of FIP but not with the common effusive form of the disease, which involves wider 
viral spread and replication than the dry form [36]. Drugs used to suppress the host 
humoral response including; glucocorticoids and cyclophosphamide could not alleviate 
the FIP signs [37]. 
Another approach of treatment is to target the virus. Ribavirin a nucleoside analog 
antiviral drug that has been tried experimentally to treat FIP but it was toxic in cats and 
resulted in severe side effects [38]. Pyridine N-oxide derivatives have been tried and 
shown to inhibit FCoV replication in vitro, however, the exact anti-coronavirus molecular 
target is not known [39]. Recently inhibitors of the viral protease have been tried to inhibit 
FIPV replication in cell culture. Protease is an enzyme encoded by the viral protease gene 
and responsible for cutting viral polyproteins into their final form, which is essential for the 
assembly of the progeny virus. Clinical trials to show the effect of protease inhibitor in FIP 
infected cats are currently lacking [40]. 
To overcome the lack of an effective treatment of this disease, various vaccination 
trials have been investigated. Unfortunately, there is only one commercially available 
vaccine for FCoV on the market. It is an intranasal vaccine containing a temperature-
sensitive mutant of FCoV that replicates in the upper respiratory tract to induce a strong 
mucosal IgA response and stimulate cellular immunity [41]. This vaccine provided 
protection in about 70% of seronegative cats, while in seropositive cats the vaccine 
showed no protection. Thus the efficiency of the vaccine is not 100% [42]. Furthermore, 
the vaccine should not be given until 16 weeks of age whereas at-risk cats often get 
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infected by 4-6 weeks of age after the maternal antibody has waned.  Other vaccination 
trials using a recombinant poxvirus that expressed the viral M protein or using live 
attenuated vaccine consisting of FIPV strains in which the 3abc or the 7ab accessory 
proteins were deleted showed either partial protection or appeared to be ineffective in 
controlling FIP [43, 44, 45]. 
 In general, prevention of FIP is dependent on preventing FECV infection because FIPV 
arises from mutant FECV.  Therefore, FECV should be eradicated from catteries and 
certain steps must be followed to achieve this goal. The chronic shedders should be 
removed, the seropositive cats should be kept in quarantine until they have cleared the 
virus, and all cats that enter the cattery should be coronavirus free as tested by real-
time, reverse-transcription PCR (RT-PCR) that can detect the viral genome in the feces 
and/or serology to determine the antibody titer. Also high hygiene standards should be 
maintained to prevent the fecal –oral transmission of the virus. Nonetheless, these 
procedures are labor intensive and not easy because of the widespread nature of the 
disease and the ease transmission of the virus [6].   
RNA Interference Review of Literature 
History RNA interference 
RNA interference (RNAi) is a natural cellular response to the presence of double 
stranded RNA (dsRNA) which results in sequence-specific silencing of gene expression 
in eukaryotes, and is considered to be a natural defense mechanism against viruses and 
transposons in some organisms. RNAi is also thought to play a role in regulating cellular 
gene expression. Since its discovery, RNAi has been developed into a widely used 
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technique for generating genetic knock-outs and for studying gene function by reverse 
genetics. The RNAi phenomenon was first discovered in 1990 in plants [46]. In an attempt 
to make the color of the flower brighter, researchers created transgenic plants in which 
the pigment making gene was over-expressed. The extra copies of this gene resulted in 
suppression of the plant endogenous gene expression as well as the transgenes. This 
phenomenon was then known as “posttranscriptional gene silencing” and “quelling”. In 
1992, a similar phenomenon was observed in Neurospora crassa, where the introduction 
of homologous RNA sequences caused quelling of the endogenous gene [47]. Later, the 
RNAi phenomenon was also documented in animals [48].   
It was thought that introduction of sense or antisense strand RNAs of certain 
endogenous genes resulted in gene suppression, but in 1998, studies showed that 
dsRNA was the source of sequence-specific inhibition of protein expression, The 
phenomenon was renamed RNAi [48]. At that time, the use of RNAi as a tool was limited 
to lower organisms because delivering long dsRNA for RNAi was nonspecifically 
inhibitory in mammalian cells as described later.  Studies later showed that the actual 
molecules that led to RNAi were short dsRNA oligonucleotides, 21 nucleotides in length, 
processed internally by an enzyme called Dicer. These short dsRNA oligonucleotides 
were termed short interfering RNAs (siRNAs), and in 2001, it was demonstrated that 
these siRNA could directly trigger RNAi in mammalian cells without evoking nonspecific 
effects. . This has resulted in the use of siRNAs in biomedical research to selectively 
knockdown genes of interest to identify and assess their functionality. Also, siRNAs have 
been considered to be a new therapeutic means to combat genetic and/or viral disease 
[49]. 
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Sources and processing of small regulatory RNAs in the RNAi Pathways 
The sequence specificity of RNAi is assured by a group of small regulatory RNAs. 
These small RNAs are classified according to their cellular origin and biogenesis 
pathways into: microRNAs (miRNAs) and siRNAs. miRNAs originate from endogenous 
genes and are involved in the regulation of development and physiological processes. In 
human about 5% of the genome encodes more than 1,000 miRNAs that regulate at least 
30% of our genes.  Whereas, siRNAs are naturally generated in some eukaryotes from 
exogenous and endogenous long dsRNAs such as infecting viruses and transposable 
elements [50]. Although  siRNA and miRNA have different origins, both types of small 
RNAs are closely related in their biogenesis, as each small RNA associates with an 
Argonaute (AGO) family protein to form a sequence-specific, gene-silencing 
ribonucleoprotein with specificity conferred by base-pairing between the small RNA and 
its target mRNA . 
Typically, the biogenesis of a miRNA occurs in the nucleus with a transcript known 
as a primary miRNA (pri-miRNA); such transcripts are at least 1,000 nt long, containing 
single or clustered double-stranded hairpins that have single-stranded 5′ and 3′ terminal 
overhangs and ∼10-nt distal loops. These stem-loops are recognized by a 
microprocessor complex, comprising Drosha, an RNase III family enzyme, and its 
cofactor DiGeorge syndrome critical region gene 8 (DGCR8), a protein containing two 
dsRNA-binding domains (dsRBDs). DGCR8 recognizes the pri-miRNA’s junction of stem 
and single-stranded RNA, which likely helps position Drosha for the endonucleolytic 
cleavage it performs on the stem ∼11 base pairs (bp) from the junction to yield a 60-nt  
precursor miRNA (pre-miRNA) containing 2- nt 3’overhangs [51, 52]. Exportin 5 
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transports this pre-miRNA to the cytoplasm. In the cytoplasm, the biogenesis pathways 
of both endogenous miRNAs and exogenous siRNAs converge. Both miRNA and siRNA 
precursors are  trimmed down to a dsRNA duplex  by Dicer, a second RNase III enzyme, 
acting in association with Tar RNA binding protein (TRBP) [53, 54]. The resulting dsRNA 
is a duplex of 21- to 25-nt strands, bearing a 2-nt overhang at each 3’ terminus and a 
phosphate at the 5’ end. Subsequently, one strand of the small RNA duplex is 
incorporated into RISC to function as a mature strand and guide RISC to target mRNAs 
[55], while the passenger strand is discarded (cleavage) [56]. Strand selection depends 
on the degree of base pairing at the duplex 5’ end; the strand less stably base paired at 
its 5’ end (has the weakest binding energy) is preferentially incorporated into RISC. The 
RISC mainly consists of three proteins; Dicer, AGO, and a dsRNA binding protein 
(dsRBP). Once the dsRNA helix is presented to AGO, the 3’ end and 5’ phosphate of the 
guide strand are bound by the AGO’s PAZ and MID domains, respectively, generating 
the RISC. Then the loaded RISC performs cellular surveillance, binding ssRNA such as 
mRNA with complementarity to the AGO-bound guide strand. Guide strand nucleotides 
2–8 from the 5’end constitute the seed sequence and initialize binding to the target [57]. 
The fate of a targeted mRNA is dependent on the degree of complementarity. Perfect 
complementarity, often observed in plants and exogenous siRNA, generally results in 
endonucleolytic cleavage of the mRNA. Imperfect complementarity, observed for most 
mammalian and viral miRNA targets, results in translational repression that can then lead 
to mRNA destabilization. RISC-bound mRNAs often localize to cytoplasmic processing 
bodies (Pbodies),which exclude the translational machinery and contain proteins involved 
in mRNA remodeling, decapping, and deadenylation, as well as exonucleases. P bodies 
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themselves, however, are not necessary for translational silencing.  Recently, data 
showed that there are several other pathways for the biogenesis of mature miRNA that 
depend mainly on AGO for cleavage of pre-miRNA to mature miRNA.   
 Viral infections and the RNAi response in mammalian cells 
Since the discovery of the RNAi phenomenon, there was an important question 
raised “Does RNAi contribute to the innate antiviral defense mechanism in mammalian 
cells?” [58] To address this question, initially, an understanding of the mammalian 
response to viral infection is needed, so a brief discussion is included.  Mammals have 
evolved highly sophisticated and effective systems of innate and adaptive immune 
responses to infections. The adaptive immune system employs receptor systems which 
have hundreds to thousands of genes that recombine and mutate to evolve highly specific 
humoral (antibody) and cell mediate immunity (T-cell) responses. The innate immune 
response involves IFNs, NK cells and macrophages. IFNs are cytokines that function as 
the host’s first line of defense against viral infection. Activation of this innate immune 
response is triggered partly by dsRNA, a common viral replication intermediate. This long 
dsRNA (>30 bases) interacts directly with cellular proteins, such as protein kinase R 
(PKR), retinoic acid-inducible gene I (RIG-1) or Toll-like receptor (TLR) which triggers 
signaling pathways that lead to the expression of type I IFNs  (IFNα and IFNβ) and the 
activation of non-specific RNases. Binding of these IFNs with their receptor leads to the 
expression of a large number of genes which leads to a generalized antiviral response at 
multiple cell levels. Expressed genes include those like 2,5 oligoadenylate synthetase 
that activates RNase L to catalyze the degradation of the viral RNA genome in non-
sequence specific manner [59]. Thus, it appears that the mammalian cell does not require 
 22 
 
the simple RNAi based antiviral mechanism to defend against viral infection. Therefore, 
RNAi machinery is mainly conserved in mammalian cells to regulate gene expression.  In 
contrast, in plants the RNAi mechanism functions as an adaptive antiviral immune 
response [58]. In plants, RNA virus infection can stimulate production of viral dsRNA-
derived siRNAs to specifically target viral genomes and mRNAs for degradation. The 
difference of function of RNAi machinery in mammalian cell and plant cell may be related 
to the difference in the composition of the RNAi machinery in both cells.  The plant cell 
has up to four dicers as compared with the mammalian cell that only has one dicer [60].  
Also in plant cell the siRNA can spread systemically to distribute its immune response 
function [61]. This systemic spread does not occur in mammalian cell due to lack of an 
RNA dependent RNA polymerase to produce additional siRNA molecules. In spite of the 
lack of natural antiviral function, studies in mammalian cell suggest that certain viruses 
can interact with cellular RNAi machinery to generate viral miRNAs [62]. These virally 
encoded miRNAs can regulate both cellular and viral genes, to lead to a successful viral 
infection. Several of the virally encoded microRNAs function to down-regulate the 
expression of factors of the innate immune system, including proteins involved in 
promoting apoptosis and recruiting effector cells of the immune system. Viruses have also 
evolved the ability to downregulate or upregulate the expression of specific cellular 
miRNAs in the favor of their replication [63].  
RNAi based antiviral therapy 
Harnessing RNAi machinery to silence disease in mammalian cells was initially 
challenging because introduction of foreign dsRNA into mammalian cell activates a 
nonspecific IFN response, as mentioned above. Nevertheless, this limitation was shortly 
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solved by using chemically modified synthetic siRNA duplexes that are too short to induce 
this non-specific inhibition (< 30 bases) [64]. Currently, siRNA can be either applied 
directly to cells or to be expressed in cells (such as short hairpin RNA (shRNA)) for 
successful RNAi in cell culture and in vivo. shRNA is short hairpin dsRNA which is created 
in the cell from a DNA construct encoding a sequence of single stranded RNA and its 
complement, which ultimately is processed to siRNA. Expression of shRNA in cells is 
typically accomplished by delivery of plasmids or through viral or bacterial vectors.   
The specificity, efficiency and the ability to design siRNA (or vector encoding them) 
to target any gene of interest shows that siRNA is a promising therapeutic tool. Using 
siRNAs that specifically target viral mRNA and/or genomic RNA for degradation by 
endogenous cellular enzymes is considered to be a powerful antiviral therapeutic 
strategy. Various viruses including; Semliki forest virus, poliovirus, dengue virus, 
influenza virus, hepatitis C virus (HCV), and SARS have been successfully targeted by 
siRNAs in vitro and ex-vivo [5, 65-68]. Despite  the great success of the RNAi study in 
vitro, the therapeutic application of this technology clinically has not progressed as well, 
because of several practical obstacles including; the potential of inducing off-target 
effects, triggering innate immune responses and most importantly delivering siRNA into 
the target cell. These obstacles are addressed in greater detail below. Despite these 
challenges, several RNAi based therapeutic approaches that target respiratory syncytial 
virus, Ebola virus, and human immunodeficiency virus (HIV), have progressed to clinical 
trials. Topical administration(via intranasal aspiration) of unmodified siRNA directed 
against the mRNA of the respiratory syncytial virus (RSV) nucleocapsid (N) protein 
showed a promising antiviral effect in phase II clinical trials [69, 70] . An anti-Ebola siRNA 
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targeting the Ebola virus RNA polymerase L protein formulated in stable nucleic acid-lipid 
particles is currently in phase I clinical trials. [71, 72]. RNAi based therapy against HIV is 
being evaluated in phase I and II clinical trials in which autologous hematopoietic cells 
are transduced ex vivo, followed by infusion back into the patient [73].  
Obstacles of RNAi based therapy 
Efficiency and specificity 
siRNA and target mRNA accessibility play an important role in achieving potent 
gene knockdown. The gene-silencing efficiency of RNAi is strongly affected by the local 
structure of mRNA at the targeted region [74]. Nucleotides in the mRNA can often form 
hydrogen bonds (i.e., becoming double-stranded) with other nucleotides in the same 
mRNA molecule, and form secondary structure (hairpin or stem) that may affect the 
accessibility of the siRNA to its target region. Therefore, computer software has been 
used to predict possible secondary structures for a given mRNA [75].  Also, it is 
recommended to stay away from target sites at either the 5’ or 3’ the mRNA, since 
proteins involved in translational regulation or mRNA processing may bind to these 
terminal regions and could interfere with the siRNA–mRNA interaction [76].  
One of the advantages of RNAi is its ability to specifically target the gene of 
interest. However, this specificity can be masked by a nonspecific effect or in another 
words the unanticipated off-target effects that may occur due to; 1) unintended 
incorporation of sense strand (passenger strand) into RISC and subsequently silencing 
of unintended targets or 2) siRNA recognition of unintended mRNAs having partial 
homology, especially in the seed region of the antisense strand (guide strand) with 
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sequences in the 3'UTR of the off-targeted gene. [77, 78].  The imperfect pairing of the 
siRNAs with unintended mRNA enables the siRNA to function as miRNA and lead to 
translational repression (miRNA like off-targeting) [77]. Although the magnitude of off-
target transcript silencing is generally lower than that of the on-target gene, small changes 
in the expression levels of host proteins, such as essential transcription factors, might 
translate to serious unintended side-effect. 
 In general, because siRNA off-targeting is concentration dependent, it is 
recommended to use siRNA at its lowest effective concentration to reduce or eliminate 
siRNA off-target effects while preserving on-target effect.[79, 80]. However, in some 
experiments, use of a low dose of siRNA did result in reduction of off-target effects, but it 
was at the expense of target gene knockdown, which was also reduced. [81]. To resolve 
this problem, siRNA combinations that include two or more potent individual siRNA that 
target the same gene have been used. Use of siRNA combinations has shown strong 
knockdown of the target gene while also significantly minimizing the off-targeting effects 
[81]. Further to avoid off-target silencing, various chemical as well as backbone 
modifications have been introduced to the siRNA structure (both the sense and antisense 
strand). On the sense strand, modifications have been made to prevent strand entry into 
RISC, thus eliminating off-target effects by this strand. Studies showed that internally 
destabilized duplexes and 5’ O- methylation of the sense strand itself impaired its 
silencing effect [82, 83]. Another strategy that has been used for strand selection and to 
abrogate gene silencing of the modified strand is locked and unlocked nucleic acid 
modified siRNAs. Locked nucleic acids are a family of conformational locked nucleotide 
analogues, where the 2′-position of the ribose is connected to the 4′-position via a 
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methylene bridge to lock the sugar backbone in the 3′-endo conformation, whereas 
unlocked nucleic acid monomers are acyclic derivatives of RNA lacking the C2–C3-bond 
of the ribose ring of RNA that lower the stability of the duplex and force the correct strand 
to into RISC [84].  
To address off-targets generated by the antisense strand, key nucleotides that are 
essential for off-targeting were modified to impair the majority of antisense strand off-
target effects, while preserving on-target knockdown. In this regard, a study showed that 
siRNAs with the seed arm replaced with a cognate DNA sequence exert very few off-
target silencing [85]. Other studies showed that a modified siRNA backbone structure with 
a single nucleotide bulge placed in the antisense strand were reported to be able to 
discriminate better between perfectly matched and mismatched targets and significantly 
reduced off-target silencing, with no loss in silencing of the intended target [86].  
Side-effects 
The RNAi phenomenon is a fundamentally important regulatory mechanism in the 
cell, and harnessing this phenomenon in the interests of therapeutic application could 
result in serious side effects and cell toxicity. Exogenously introduced siRNA/shRNA 
sequences utilize the components that make up the cellular RNAi machinery involved in 
gene regulatory mechanism, thereby reducing the accessibility of the machinery to the 
cellular miRNAs that are essential for regulating the cellular gene expression [87, 88].  
In addition to the off-target effects, mentioned earlier, studies have shown that 
siRNAs can be recognized by the host innate immune response and stimulate the 
production of pro-inflammatory cytokines and type I IFN, which may predispose to a 
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pathological inflammatory response [89]. Studies have shown that some siRNAs can be 
recognized by TLR3 that recognize dsRNA in a sequence-independent pattern or 
recognized by TLR7 and 8 that recognize ssRNA in sequence dependent pattern. Due to 
the primary localization of TLR in the endosomal compartment, these receptors most 
readily recognize and bind ligands during internalization of siRNAs delivered by cationic 
lipids and polymers [90]. Other delivery system such as electroporation, hydrodynamic 
delivery, or peptide transduction can bypass transit through this compartment and can 
evade recognition by these receptors. The other receptors that can recognize foreign 
RNA including PKR and RIG-I are localized in the cytoplasm and mainly recognize dsRNA 
which are longer than traditional siRNAs (>30 nt) or have different end structures than 
standard siRNAs. For example, RIG-I recognizes a 5′-triphosphate end, which is 
generated in vivo during viral replication but is not triggered by the 5′-cap structure present 
on mammalian RNA. Long dsRNAs naturally exist within mammalian cells and these 
usually do not elicit an immune response; this is achieved by exclusion of these RNAs 
from endosomal TLRs and endogenous chemical modification [90]. Sugar modifications, 
such as 2′O Methylated RNA, and some base modifications, such as pseudouridine, are 
common in mammalian tRNAs and rRNAs to help these RNAs to evade initiating an 
autoimmune response. Likewise, there are various chemical modification strategies 
(mentioned earlier) that can enable the synthetic siRNAs to evade the immune system 
detection [91]. Indeed, better understanding of the mechanisms that drive the 
immunostimulatory properties of the siRNA as well as the recognition pathway is very 
important to overcome this side effect. 
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 Viral escape mutants 
Viruses have a unique ability to develop resistance to antiviral drugs. Viruses, 
especially RNA viruses replicate with high mutation rates that result in genetic diversity 
and evolution of resistance to antiviral therapy. Therefore, it is not surprising to know that 
viruses have great ability to escape from RNAi inhibition as well. Single mismatches within 
the targeted region, or even its entire deletion, resulted in escape from RNAi inhibition 
effect by poliovirus, HCV and HIV-1 [92-94]. The location of the point mutation in the 
target sequence determines the level of resistance. 100% homology in the seed region 
nt 2 - 8 in the guide strand are important for target recognition so any mutation in this 
region may affect the siRNA inhibition efficiency. However, a few mutations within the 3’ 
and 5’ ends of the target sequence can be tolerated. Therefore, differences observed in 
the level of resistance conferred by point mutations are associated with the location of the 
mutation in the target sequence. The basis for this positional resistance difference is 
related to the mechanism of incorporation of the siRNA into the RISC and its AGO protein 
induced cleavage. To overcome this limitation, combinations of different siRNAs have 
been used to delay viral escape of poliovirus and HCV [92, 93]. Further, targeting multiple 
genes has been shown to be more effective than targeting a single gene. However, with 
use of multiple siRNAs, the RNAi machinery may become saturated, with no boosted 
effect.  
A second approach to overcome viral escape mutants is to target highly conserved 
genes that are essential for viral replication, as mutation in these regions could lead to a 
deleterious effect on the virus [95]. Thus, targeting these regions may prevent or delay 
viral escape mutant development. Nevertheless, silent mutations that lead to changes in 
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nucleotides but not in amino acids may occur in these regions without compromising the 
viral replication ability and allow the virus to escape the RNAi inhibition effect. The UTRs 
of RNA viruses are considered to be a good example of a highly conserved region. 
However, it is important to determine the susceptibility of viral untranslated regions 
because interaction in the UTRs with proteins or RNAs might shield them from RISC 
mediated recognition and cleavage.  A third approach to prevent virus escape is to target 
the host factors required for virus replication, such as the virus receptor [96]. Indeed, it 
seems that combination of these three approaches will be very effective in preventing 
virus escape mutants. 
Viral suppressors of RNAi 
Across eukaryotes including; plants, Drosophila, mosquitoes, nematode worms 
and fungi, antiviral RNAi directed by virus-derived siRNAs represents a major antiviral 
defense that the invading viruses have to overcome in order to establish infection. As a 
counter defense mechanism, viruses of these hosts express proteins termed viral 
suppressors of RNAi (VSRs) that can block the biogenesis and/or function of viral siRNAs. 
VSRs may inhibit the viral RNAi pathway at various stages and in multiple ways. Some 
bind dsRNA and sequester siRNAs away from the RNAi pathway such as P10 of 
vitiviruses. In some viruses the VSRs either bind to or degrade AGO, to prevent the RISC 
from cleaving target RNA such as 2b protein of cucumoviruses and P0 of poleroviruses 
respectively. Others VSRs inhibit cell-to-cell signalling of immunity, such as the P30 of 
tobamoviruses [97]. 
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 In mammalian cells, though siRNA is not a natural defense mechanism, some 
research suggests mammalian viruses have evolved mechanisms that suppress 
RNAi. This RNAi suppression mechanism may be raised to subvert the effect of the 
cellular miRNAs that may interfere with virus replication. Since cellular miRNAs are highly 
conserved during evolution it seems unlikely that viruses would fail to evolve mechanisms 
to prevent their inhibitory effect. In mammalian cells, good example is adenovirus. 
Adenovirus has developed several strategies to target the RNAi pathways during infection 
through its viral associated RNAs; VA RNAI and VA RNAII.  VA RNAs are short RNA 
polymerase III transcripts which have highly folded structure with imperfect stem that 
resemble cellular pre-miRNAs. Therefore, the VA RNA is able to interfere with the 
RNAi/miRNA pathways both at the level of pre-miRNA processing and RISC assembly. 
The VA RNAs are produced in a high abundance, enabling them to act as a competitive 
substrate for dicer, and as a consequence, they become a preferred substrate for RISC 
assembly. Further, it has been shown that the terminal stem of VA RNAi binds to the 
Exportin-5 receptor and therefore, reduces the efficacy of cellular pre-miRNA binding to 
Exportin-5 and its transportation from the nucleus to the cytoplasm [62].  
Influenza virus has been shown to suppress RNAi in plants and in Drosophila but not in 
mammalian cells [98]. Although various virus-encoded RNAi suppressors have been 
identified, recently, some of these suppressors have been questioned and the ability of 
mammalian viruses to suppress RNAi pathway in natural host cells has remained 
controversial. 
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Delivery 
Safe and effective delivery of siRNA to the target sites and then into cells is one of 
biggest challenges preventing siRNA clinical applications. In this regard, viruses differ 
greatly with respect to cell and tissue tropism, which will pose further hurdles to the 
delivery challenge. For example, chronic systemic viral infections require systemic, 
prolonged expression or repeated delivery of siRNAs. However, local delivery of siRNAs 
is feasible for the treatment of acute viruses with a relatively restricted tissue tropism, 
such as RSV, parainfluenza virus and influenza [67, 99]. Indeed, local regional delivery 
of siRNAs has fewer barriers compared to systemic delivery. siRNA is short double-
stranded RNA with a net negative charge, which makes it difficult to transfect into cells. 
Additionally, siRNA is rapidly degraded by nuclease activity in plasma and cells, and 
siRNA is also rapidly excreted by the kidneys. Therefore, as previously described, several 
types of chemically modified siRNAs have been developed to not only minimize off-target 
effects and inhibit immune system stimulation, but these modifications also improve the 
siRNAs stability to nuclease and its pharmacokinetic properties [100].  Several studies 
have indicated that chemically modified siRNAs can maintain potency and show 
increased serum stability beyond 72 hours whereas the same sequence in unmodified 
form is completely degraded in just 5 hours in mouse serum.  
The delivery system used for uptake of the negatively charged siRNAs into the 
cells can also provide stability against nucleases in the serum. In addition an ideal delivery 
system should be able to provide: evasion of the immune system, avoidance of non-
specific interactions with serum proteins and non-targeted cells, prevention of renal 
clearance, and exit from blood vessels to reach target tissues. Once internalized into the 
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cells, the siRNA must be able to release from the delivery system in a reversible manner 
to conserve its activity in the cytosol, incorporate into the RISC and induce gene silencing.  
To achieve effective siRNA delivery, several delivery systems have been 
developed and examined. These delivery systems can be classified into two main groups; 
viral and non-viral delivery systems. Viral delivery systems are mostly used to deliver 
DNA-based expression cassettes that express shRNA. There are five groups of viral 
delivery systems used for RNAi (Retrovirus, Lentivirus, Adenovirus, Adeno-Associated-
Virus (AAV), and Baculovirus). Although viral delivery systems have high transduction 
efficacy, due to the inherent ability of viruses to transport genetic material into cells, the 
potential of mutagenicity or oncogenesis, inflammation and host immune responses, 
limited viral loading capacities and high cost hinder their application [101]. For these 
reasons, different non-viral siRNA delivery systems have been developed including; 
cationic carrier, nanoparticles and cell-penetrating peptides (CPPs) [102, 103].  
Positively charged cationic liposomes and polymers have been shown to be able 
to deliver siRNAs through the cellular membrane and achieve a high level of RNAi [104]. 
However, the highly positive surface charges of these molecules tend to interact with the 
erythrocytes and/or serum proteins, leading to aggregation with erythrocytes and bad 
pharmacokinetics, mainly due to the rapid uptake of these aggregates by the 
mononuclear phagocytic system [90]. In some cases this interaction has been used to 
enhance the delivery to certain tissue and cell types. For example, many liposomal 
delivery systems, as well as siRNA conjugated to lipophilic molecules, interact with serum 
lipoproteins and subsequently gain entry into hepatocytes that take up those lipoproteins 
[105]. Means to improve the cationic delivery vehicles have been explored, including use 
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of hydrophilic polymerases such as polyethylene glycol (PEG), which was used to shield 
the cationic vehicles to increase circulation time and minimize non-specific interactions of 
particles with serum proteins, cells of the innate immune system and other non-targeted 
tissues [106]. Despite the improvements, the use of cationic carriers as delivery vehicle 
is limited in vivo because of their toxicity.  Use of cationic liposomes in vivo was shown to 
elicit dose-dependent toxicity and pulmonary inflammation by promoting release of 
reactive oxygen intermediates [107].  
Another widely used cationic delivery vehicles is polyethyleneimine (PEI). PEI is a 
synthetic polymer that has strong buffering capacity and can increase the endosomal 
escape of the siRNA, consequently preventing enzymatic degradation and TLR mediated 
immunological response in endosomes/lysosomes. However the toxic effect caused by 
the non-degradable nature of this synthetic polymer limits its wide application in vivo. 
Recently, various synthetic cationic liposomes and polymers-based nanoparticles have 
been developed that offer enhanced transfection efficiency combined with reduced 
cytotoxicity, as compared to traditional ones. The incorporation of distinct layers 
composed of lipid molecules with varying physical and chemical characteristics into the 
polymer nanoparticle formulation resulted in improved RNAi efficiency through better 
fusion with cell membrane and entry into the cell, enhanced release of RNAi molecules 
inside the cell, and reduced intracellular degradation of RNAi-nanoparticle complexes 
[108].  
In general, various delivery systems improved the rate of cellular uptake by 
incorporating targeting ligands that bind specifically to receptors on target cells to induce 
receptor-mediated endocytosis [109]. Other systems use cationic CPPs, such as 
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transporten (a chimeric peptide composed of galanin and mastoparan), penetratin (from 
Drosophila) or TAT (Peptides derived from the transactivating regulatory protein of HIV), 
the VP22 protein from herpes simplex virus and polyarginine [110-112]. The strong 
positive charge on these peptides promotes binding and condensation of negatively 
charged siRNA, allowing CPPs to be used for the delivery of siRNA into a variety of 
cultured cells through endocytosis or non-endocytic mechanism with minimal toxicity 
[113]. Most siRNA delivery systems undergo cellular internalization through endocytosis. 
Endocytosed materials are taken up into membrane-bound endocytic vesicles, which fuse 
with early endosomes and become increasingly acidic as they mature into late 
endosomes. Some delivery systems incorporate materials that are designed to respond 
to this low-pH environment by becoming membrane-disruptive in order to trigger the 
release of siRNA from endosomes into the cytoplasm.  
Development of an efficient delivery system is one of the most challenging 
obstacles to turn siRNAs into clinical therapeutic applications. Many different siRNA 
delivery systems were synthesized, characterized and their gene silencing efficiency were 
tested in vitro and in vivo, and some of them have showed a promising results. Indeed, 
the improvement in siRNAs designs rules and the continuous progress in the 
development of new delivery system will lead to promising clinical application of RNAi as 
antiviral therapy.  
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Chapter 2 
Effectiveness of Small Interfering RNA (siRNA) to 
Inhibit Feline Coronavirus Replication in Vitro 
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Abstract 
Feline coronavirus (FCoV) is an enveloped, single-stranded RNA virus which is 
ubiquitous in domestic cat populations worldwide. Mutation of FCoV to a biotype that has 
the ability to replicate in the macrophages and monocytes results in the development of 
feline infectious peritonitis (FIP). FIP is an invariably fatal disease that is considered to be 
the major cause of infectious death in young cats. To date there is no effective treatment 
for FIP affected cats. 
 In this study, we evaluated the ability of siRNA to inhibit the in vitro viral replication 
and gene expression of FCoV. Five synthetic siRNAs targeting five different regions of 
the FCoV genome were screened for their antiviral effects against two different strains of 
FCoV; FIPV WSU 79-1146 and FECV WSU 79-1683. Efficacy was assessed by flow 
cytometric evaluation of the reduction of viral protein expression in infected cells and 
relative quantification of the inhibition of intracellular viral genomic RNA synthesis by 
means of real-time, reverse-transcription PCR analysis. 
The 5 examined siRNAs targeted the leader sequence, untranslated region, 
replicase gene, membrane gene, and nucleocapsid gene. These siRNAs exhibited a 
variable inhibitory effect on viral replication in vitro and resulted in decreases in the protein 
expression of FIPV WSU 79-1146 and FECV WSU 79-1683. These preliminary findings 
shows that FCoV translation and replication can be specifically inhibited  using siRNA 
targeting coding and noncoding region of viral genome, suggesting a potential therapeutic 
application of RNAi in treating FIP. 
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Introduction 
Feline coronavirus (FCoV) infection is common in domestic cats and usually 
causes subclinical or mild enteritis. Primarily, FCoV targets intestinal epithelial cells and 
is shed in feces of infected cats, often continuously or intermittently for months or years 
[6]. In certain cats, virus mutation may occur that allows the virus to replicate efficiently in 
monocytes and macrophages, resulting in the development of FIP [8]. FIP is a fatal 
progressive disease that is manifested in two lethal forms; the effusive form and non-
effusive form [6]. To date, therapeutic possibilities for cats with FIP are extremely limited 
and do not specifically target the virus. Therefore, development of a new therapeutic for 
FIP would be valuable. Recently, a novel antiviral strategy has been developed that 
utilizes siRNAs to specifically target viral mRNA and genomic RNA (gRNA) for 
degradation. siRNA utilize the cellular machinery for gene silencing in a sequence 
dependent manner [4]. This technology has been employed successfully for viral 
diseases such as human immunodeficiency virus (HIV), viral hepatitis and severe acute 
respiratory syndrome (SARS) both in vitro and in vivo [114-116].  
 Given the important role of increased FCoV replication during the pathogenesis 
of FIP, it is likely that the development of siRNAs that specifically target the virus and limit 
its replication will help in treating this fatal disease. The objectives of our study were to 
design a panel of feline coronavirus-specific siRNAs that can hybridize to viral coding or 
noncoding regulatory regions of the genome and screen synthesized siRNAs for their 
effectiveness in inhibiting FCoV replication in cell culture. Inhibition of viral growth was 
measured by quantitative real-time RT-PCR for relative quantification of the inhibition of 
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intracellular viral genomic RNA synthesis and flow cytometry for evaluating the reduction 
of viral protein expression in infected cells.  
Materials and Methods 
Cell culture and viruses 
Crandell-Rees feline kidney cells (CRFK)a were propagated in DMEM/F-
12bsupplemented with 10% heat inactivated fetal bovine serumc and maintained at 37°C 
and 5% CO2 in an incubator. 
Two different strains of FCoV; FIPV WSU 79-1146d and FECV WSU 79-1683e 
were used for the study. Working stocks viruses were produced in CRFK cellsa and 
quantified by plaque assay. Plaque assays were performed by inoculating monolayers of 
CRFK cellsa in 96-well plates with 100 µl of ten-fold virus dilutions. After adsorption for 1 
hour at 37 °C the cells were overlaid with 100 µl of 0.75% carboxymethylcellulose. After 
96 hours incubation, plaques were counted. Virus stocks were stored at -80 °C until use 
and each aliquot was used only once for each experiment. 
siRNAs design 
Five siRNAsf (Table 2.1) were designed based on published sequence data for 
FCoV using an RNAi designerg. siRNA-L that targets the common 5′ leader region, 
siRNA-U that targets the common 3′ UTR, siRNA-R that targets the replicase gene, 
siRNA-M that targets the membrane gene, and siRNA-N that targets the nucleocapsid 
gene. The sequences of these siRNAs were confirmed for specificity by comparing them 
with FCoV sequences in GenBank database. Also the sequences of the siRNAs were 
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selected to have a minimal homology to cat genome available in GenBank.  The stealth 
siRNAsf used in this study were chemically modified to reduce off-target and nonspecific 
effects, eliminate the induction of the interferon response pathway, minimize nonspecific 
cellular stress, and to be highly specific and stable in serum [117]. 
Optimization of transfection conditions 
To optimize transfection condition and obtain the highest transfection efficiency, 
80% confluent CRFK cells in 12-well plates were transfected with 30 nM fluorescein 
labeled siRNAh/well.  Transfection was performed with increasing concentrations of the 
transfection agenti (1.5 µL, 3 µL and 5 µL/well of transfection reagent) according to the 
manufacturer’s protocol i. Then, 24 hours following transfection, cells were trypsinized and 
pelleted (1000 x g). Finally, the cells were resuspended in 500µl phosphate-buffered 
saline (PBS) per sample and the intracellular fluorescein was measured using flow 
cytometry. 
Optimization of siRNA concentration 
The quantity of siRNA used for transfection is very important to obtain the highest 
transfection efficiency. To optimize the concentration of siRNA, 80% confluent CRFK 
cellsa  in 12-well plates were transfected with increasing concentration of either siRNA-L 
or siRNA-M (30 nM, 50nM and 100nM siRNA/well)  and 1.5µL/well of transfection reagent. 
After 24 hours, cells were either infected with FIPV WSU 79-1146d or FECV WSU 79-
1683e virus at MOI 0.1.  One hour after incubation the cells were washed with DMEM/F-
12b and fresh DMEM/F-12b with supplemental 10% heat inactivated fetal bovine serumc 
was added to each well.  After 48 hours cultured cells were harvested and FCoV protein  
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Table 2.1— Sequences of siRNAs (and their position within the FIPV WSU 79-1146 
genome based on GenBank accession No. DQ010921) used in experiments to evaluate 
the ability of siRNAs to inhibit in vitro viral replication and gene expression of FIPV WSU 
79-1146 and FECV WSU 79-1683. 
 
siRNA Nucleotide sequence 
Position in the 
genome (bp range) 
siRNA-L   
Sense UCUUCGGACACCAACUCGAACUAAA 74–98 
Antisense 
 
UUUAGUUCGAGUUGGUGUCCGAAGA  
siRNA-M   
Sense GACCACAAUUUAGCUGGCUCGUUUA 26198–26222 
Antisense 
 
UAAACGAGCCAGCUAAAUUGUGGUC  
siRNA-R   
Sense CAUUGCAGCUUUGAGUACUGGUGUU 13330–13354 
Antisense 
 
AACACCAGUACUCAAAGCUGCAAUG  
siRNA-N   
Sense GACAACUUUCUAUGGUGCUAGAAGU 27507–27531 
Antisense 
 
ACUUCUAGCACCAUAGAAAGUUGUC  
siRNA-U   
Sense GAGGUACAAGCAACCCUAUUGCAUA 28941–28965 
Antisense UAUGCAAUAGGGUUGCUUGUACCUC  
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expression was measured using flow cytometryl as described below.  
siRNA transfection and virus infection 
 80% confluent CRFK cells in 12-well plates were transfected with 100 nM 
siRNA/well and 1.5µL/well of transfection reagent. Cells were either infected with FIPV 
WSU 79-1146g or FECV WSU 79-1683h virus at MOI 0.1, 24 hours after transfection.  One 
hour after incubation the cells were washed with DMEM/F-12b and fresh DMEM/F-12 b 
with supplemental 10% heat inactivated fetal bovine serumc was added to each well.  After 
48 hours cultured cells were harvested for relative quantification of intracellular FCoV 
genomic RNA and viral protein expression.   Control samples used in each experiment 
included FCoV-infected cells and untreated CRFK cells. Also, FCoV-infected cells treated 
with a negative control siRNAa that is non-targeting were included as controls to test for 
potential nonspecific effects. CRFK cells were also mock transfected, using the 
transfection agent only, to evaluate for potential toxic effects. Each siRNAa was tested in 
duplicate, and each experiment was performed twice.  
Flow cytometry analysis 
To assess virus protein expression in infected cells, 48 hours after viral infection, 
CRFK cells in each test and control well were trypsinized, washed with PBS, and 
resuspended in 1 mL of PBS per sample. 100μL of each suspension was removed and 
placed on ice for later RNA extraction and the rest of each sample was processed for flow 
cytometry. 
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 The flow cytometry samples were first treated with a permeabilization reagent j 
according to manufacturer’s protocol. Then the cells were stained with 200 µl of FITC-
labeled FCoV polyclonal antibodyk for 30 minutes on ice in the dark. Then the cells were 
washed with PBS, pelleted (1000 x g), and resuspended in 500µl PBS. Finally, FCoV 
protein expression was measured as the intensity of fluorescence using flow cytometryl.  
Quantitative real-time RT-PCR 
For cellular viral RNA quantification, cells were harvested 48-hours following virus 
infection and nucleic acid was extracted using an RNA purification kit m according to 
manufacturer recommendations. Briefly, samples were first lysed and homogenized using 
a homogenizern. Then the lysate was passed through a gDNA eliminator spin column 
provided with the kit that selectively and efficiently removes genomic DNA. Purified RNA 
samples were stored at -80°C until tested by real-time RT-PCR.  
Reverse transcription and quantitative PCR was done using previously published 
primers and a FAM-labeled probe targeting the 7b coding region, as this region is highly 
conserved in FCoV [118]. Reactions were done using a qRT-PCR Kito in a thermal cyclerp 
as follows; 5 μL of extracted RNA was used in 25 μL total volume reactions, which 
contained 200nM of each probe and 300nM of each primer, and 40U of recombinant 
ribonuclease inhibitorq. Cycling parameters were as follows: cDNA production at 42ºC for 
30 min, hot start Taq polymerase activation at 95ºC for 2 minutes, followed by 45 cycles 
of denaturation at 95ºC for 10 seconds, annealing at 60ºC for 40 seconds, and extension 
at 72ºC for 30 seconds.  
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To standardize the total amount of RNA in each reaction, mRNA expression of the 
housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used to 
allow relative quantitation of the viral RNA by the 2-ΔΔCt  method [119].   
Statistical analysis 
All statistical testsr were done using ANOVA to compare and test for significant 
mean differences between treated samples and the negative control non-targeting siRNA, 
FCoV-infected samples. The ANOVA assumption of normality was tested using the 
Shapiro-Wilk statistic. When this assumption was not met, a log transformation of the data 
and/or ANOVA on rank transformed data was done, and the Levene’s test was used to 
test the ANOVA equality of variance assumption. Bonferroni adjustment was used to 
minimize the Type I error rate.  Fisher’s Least Significant Difference (LSD) method of 
mean separation was used to determine which means differed significantly.      
Results 
Optimization of transfection condition 
CRFK cells were 95% effectively transfected with 1.5 µL of the transfection 
reagent. Further, to optimize the concentration of the siRNAs that will be used throughout 
the study, cells were transfected with increasing concentration of either siRNA-L or 
siRNA-M. The transfection was performed with 1.5 µL of the transfection reagent. Both 
tested siRNAs demonstrated concentration dependent inhibition of viral protein 
expression as evaluated by the flow cytometery. Reductions in viral protein expression 
were increased at 100nM of the siRNA. To this end, transfection of CRFK cells was 
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optimized at 100nM siRNA in combination with 1.5 µL of the transfection reagent to obtain 
optimal target gene reduction. 
Effect of individual synthetic siRNAs on FCoV protein expression in CRFK cells 
The 5 siRNAs–siRNA-L, siRNA-U, siRNA-R, siRNA-M, and siRNA-N–used in this 
study exhibited a variable inhibitory effect on viral replication in vitro, resulting in 
decreases in the protein expression of FIPV WSU 79-1146 by 80 ± 11%, 43 ± 23%, 13 ± 
11%, 33 ± 7%, and 50 ± 17% respectively (Fig. 2.1). siRNA-R had no effect on the protein 
expression of  FECV WSU 79-1683 while siRNA-L, siRNA-U, siRNA-M, and siRNA-N  
resulted in 75 ± 6%, 30 ± 11%, 14 ± 5%, and 13± 0.9% decreases in viral protein 
expression, respectively, compared with the negative control non-targeting siRNA, FCoV-
infected sample (Fig. 2.2).   
Inhibition of viral genomic RNA by individual synthetic siRNAs 
siRNA-L, siRNA-U, siRNA-N showed 99%, 75% and 47% reduction in FIPV WSU 
79-1146 genomic RNA and 96%,41% and 35 % reduction in FECV WSU 79-1683, 
respectively. While, siRNA-R and siRNA-M had no inhibitory on the replication of viral 
genomic RNA, (This data is the result of one experiment in which each siRNA treatment 
was assessed in duplicate). 
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 Figure 2.1— Results of flow cytometric analysis to illustrate the effect of individual 
siRNAs on the expression of FIPV WSU 79-1964 protein in virus-infected CRFK cells (the 
Y axis represent the relative viral protein expression (%)). The CRFK cells were 
transfected with 1 of 5 screened siRNAs (concentration, 100nM) or a negative control 
non-targeting siRNA 24 hours prior to viral infection (MOI, 0.1). At 48 hours after viral 
infection, CRFK cells were stained with labeled anti–FCoV polyclonal antibody following 
a standard protocol, and cell fluorescence was assessed by flow cytometry. The data 
represent the result of 2 independent experiments, each sample was assessed in 
duplicate. 
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Figure 2.2—Results of flow cytometric analysis (% viral protein expression on the Y axis) 
to illustrate the effect of individual siRNAs on the expression of FECV WSU 79-1683 
protein in virus-infected CRFK cells (the Y axis represent the relative viral protein 
expression (%)). The CRFK cells were transfected with 1 of 5 screened siRNAs 
(concentration, 100nM) or a negative control nontargeting siRNA 24 hours prior to viral 
infection (MOI, 0.1). At 48 hours after viral infection, CRFK cells were stained with labeled 
anti–FCoV polyclonal antibody following a standard protocol, and cell fluorescence was 
assessed by flow cytometry. The data represent the result of 2 independent experiments, 
each sample was assessed in duplicate 
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Discussion 
Inhibition of FCoV replication using the RNAi phenomenon provides a promising 
therapeutic application against the fatal FIP disease which is caused by a mutant FCoV 
biotype.  FCoV is considered a good target for siRNA treatment, as the viral full-length 
genome contains nearly all the sequences found in any of the sgRNAs [18]. Thus the 
siRNA that targets the sgRNAs will target the full-length genomic RNA too. In spite of that, 
the development of siRNA-based FCoV strategy faced several challenges. An obvious 
challenge is the selection of an appropriate target within the viral RNA genome that can 
be used for all viral strains.  Coronavirus has the largest animal RNA genome and is prone 
to a high mutation rate [120]. Therefore, there are various FCoV strains circulating in the 
field. To overcome this limitation we designed and screened the ability of five siRNAs that 
target various highly conserved viral non-coding and coding regions. siRNA-L targets the 
leader sequence, which is highly conserved in FCoV and plays a pivotal role in virus gene 
expression and replication [121]. siRNA-U, targets the 3′ UTR. This non-coding region is 
highly conserved in FCoV and plays an essential role in regulating the viral transcription 
and replication cycle. The earliest steps of both genome replication and sgRNA 
transcription initiate at the 3′ end of the genome, which makes it an important siRNA target 
[18]. siRNAs that target viral coding regions include; siRNA-R, siRNA-M and siRNA-N. 
siRNA-R targets the viral replicase gene, which encodes the viral nonstructural replicase 
that plays a critical role during the virus replication. siRNA-N and siRNA-M, target the viral 
structural nucleocapsid gene and membrane gene. These five siRNAs exhibited a 
variable inhibitory effect on FCoV replication in vitro as compared with the negative 
control non-targeting siRNA sample. siRNA-L exhibited the highest inhibitory effect on 
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FCoV protein expression, followed by siRNA-U and siRNA-N. The leader sequence is 
present in the 5’end of each viral mRNA as well as the viral genome [18].  Therefore 
siRNAs directed against the regulatory leader sequence can target genomic RNA as well 
as all viral mRNA species and has been reported as an effective method for inhibiting 
coronavirus replication using an in vitro SARS-CoV model [122]. All these screened 
siRNAs except siRNA-R and siRNA-M resulted in inhibition of the viral protein expression 
as well as the viral genomic RNA. siRNA-R and siRNA-M showed low inhibitory effect on 
the viral protein expression(siRNA-M) and no effect on the viral genome replication. Using 
M –fold software that predict the secondary structure of single stranded nucleic acid 
showed that the target sites of the replicase and membrane genes have the ability to self- 
anneal and to develop secondary structure that is known to interfere with and/or inhibit 
the siRNA effect. Further, the low inhibitory effect of siRNA-M on the viral protein 
expression may be attributed to the degradation of viral sg (mRNA) that encodes the viral 
membrane protein and not because of the degradation of the viral full length genome. 
The difference in RNA secondary structure between the sg (mRNA) and the viral genomic 
RNA seems to play role in limiting target accessibility. 
Development of viral escape mutants is another important challenge that faces 
siRNA-based antiviral therapy. Selecting and targeting highly conserved regions can 
minimize this challenge. Highly conserved regions are critical for the viral life cycle and 
therefore do not tolerate nucleotide changes and is highly conserved among the different 
virus strains. However, any silent point mutation in these critical conserved regions might 
affect the efficiency of the siRNA. Thus, further strategies are required to minimize the 
development of escape mutants. The use of multiple siRNA targets in combinations has 
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been demonstrated to dramatically decrease the ability of the virus to develop escape 
mutants and resist the siRNA inhibitory effect [93].  
These preliminary findings shows that FCoV replication can be specifically 
inhibited using siRNA targeting coding and noncoding region of viral genome. 
Identification of siRNAs that specifically targets FCoV is necessary to develop siRNA 
technology into an effective anti-FCoV therapy and treat FIP disease for which there is 
no specific treatment. 
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Chapter 3 
siRNA Combinations Inhibit Feline Coronavirus 
Replication and Expression in Cell Culture 
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Abstract 
Feline infectious peritonitis (FIP) continues to be a significant cause of mortality in 
cats. Feline coronavirus (FCoV), the agent of FIP, primarily targets intestinal epithelial 
cells, but in certain cats, virus mutation may occur that allows the virus to replicate 
efficiently in monocytes and macrophages, resulting in FIP development to which 
currently, there is no specific effective treatment.  
  In this study, we evaluated the ability of siRNA combinations to inhibit FCOV 
replication and expression in vitro. Three combinations of previously screened individual 
siRNAs were tested for their antiviral effects against two different strains of FCoV. Efficacy 
of the siRNAs combinations was determined by 1) quantification of the inhibition of 
intracellular viral genomic RNA using real time RT-PCR, 2) evaluation of the reduction of 
viral protein expression in infected cells using flow cytometry and 3) assessment of virus 
replication inhibition in cell culture via titration of extracellular virus using TCID50 assay.  
Combinations of siRNAs tested included; siRNA-L (targeting the FCoV leader 
region) and siRNA-U (targeting the 3′ untranslated region); siRNA-L and siRNA-N 
(targeting the nucleocapsid gene); and siRNA-L, siRNA-U, and siRNA-N. These 
combinations resulted in more than 99.5%, 98.7%, and 98.4% reduction in viral 
replication, respectively, in comparison to siRNA negative control cells, based on virus 
titration results. These preliminary findings show that FCoV replication can be specifically 
inhibited using siRNAs combinations targeting various regions of the viral genome, 
suggesting a promising therapeutic application of siRNA in treating FIP. 
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Introduction 
Given the central role played by the increased virus replication in the development 
of FIP, antiviral therapy that specifically targets the virus and reduces its replication could 
effectively help treat this highly fatal disease. In the previous chapter, we showed the 
ability of individual siRNAs that each target a single region to inhibit the replication of 
FCoV.  Improvement of the inhibitory effect of these siRNAs can be achieved by 
combining the most effective siRNAs into combinations. The use of siRNA combinations 
that target various regions has been reported to have a synergistic effect, help to reduce 
off-target effects of the siRNA and prevent the development of escape mutants that may 
resist the effect of the designed siRNA [123]. To achieve this objective, three 
combinations of previously screened siRNAs (siRNA-L, siRNA-U and siRNA-N) have 
been examined and their efficiency were assessed via relative quantification of the 
inhibition of intracellular viral genomic RNA synthesis by means of real-time, reverse-
transcription PCR analysis; flow cytometric evaluation of the reduction of viral protein 
expression in infected cells; and assessment of virus replication inhibition via titration of 
extracellular virus with a TCID50 assay.   
Material and methods 
Selection of siRNA combinations 
The selection of the siRNA combinations was based on the percentage of in vitro FCoV 
inhibition. The three siRNAs, siRNA-L, siRNA-U and siRNA-N, which gave better viral 
inhibition as compared with the other examined siRNAs were included in the screened siRNA 
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combinations. The tested siRNA combinations included siRNA-L (targeting the FCoV leader 
region) and siRNA-U (targeting the 3′ untranslated region [C1]); siRNA-L and siRNA-N 
(targeting the nucleocapsid gene C2]); and siRNA-L, siRNA-U, and siRNA-N (C3).  
Cell culture, transfection, and virus infection 
Crandell-Rees feline kidney cellsc were propagated in a DMEM-based nutrient 
solutiond   supplemented with 10% heat-inactivated fetal bovine serume and maintained 
at 37°C and 5% CO2 in an incubator. The cells were plated in 12-well plates, then 
transfection was performed at about 80% confluency with siRNA combinations and 
transfection reagentf (1.5 µL/well). In each well 2 or 3 siRNAs were combined to provide 
a total concentration of 100nM/well. Twenty-four hours following transfection, cells were 
either infected with FIPV WSU 79-1146g or FECV WSU 79-1683h virus at an MOI of 0.1.  
One hour after incubation, the cells were washed with DMEM-based nutrient solution, 
and fresh DMEM-based nutrient solution with supplemental 10% heat-inactivated fetal 
bovine serum was added to each well.  After 48 hours, samples of cell culture medium as 
well as cultured cells were collected for viral titration, relative quantification of intracellular 
FCoV genomic RNA, and assessment of viral protein expression.   Control samples used 
in each experiment included FCoV-infected cells and untreated CRFK cells; FCoV-
infected cells treated with a negative control non-targeting siRNAa were also included as 
controls to test for potential nonspecific effects. Fluorescein-labeled siRNAi was used to 
evaluate transfection efficiency. The CRFK cells underwent mock transfection with the 
transfection agent only to evaluate for potential toxic effects. Each siRNA and siRNA 
combination was tested in duplicate, and each experiment was performed twice.  
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Flow cytometry analysis 
Forty-eight hours after viral infection, siRNA treated and control CRFK cells were 
treated with a permeabilization reagent j (according to manufacturer’s protocol) to assess 
virus protein expression. The cells were stained with 200 µL of fluorescein isothiocyanate-
labeled anti–FCoV polyclonal antibodyk for 30 minutes on ice in the dark. The cells were 
washed with PBS solution, pelleted by centrifugation (1,000 X g), and resuspended in 
500 µL of PBS solution. Finally, FCoV protein expression was measured as the intensity 
of fluorescence detected by flow cytometry.l Experimental controls included cells 
transfected with negative control nontargeting siRNA-treated, FCoV-infected cells, or 
uninfected cells. 
Quantitative real-time RT-PCR assay 
For cellular viral RNA quantification, cells were harvested 48 hours following virus 
infection, and nucleic acid was extracted with an RNA purification kitm according to 
manufacturer recommendations. Briefly, samples were first lysed and homogenized using 
homogenizern. Then the lysate was passed through a gDNA eliminator spin column 
provided with the kit that selectively and efficiently removes genomic DNA. Purified RNA 
samples were stored at -80°C until tested by real-time RT-PCR. 
  Reverse transcription and quantitative PCR assays were performed with primers 
and a FAM-labeled probe that targets the 7b coding region, a region that is highly 
conserved in FCoVs [118]. Reactions were done with a quantitative RT-PCR kitn in a 
thermal cycler.o as follow; 5 μL of extracted RNA was used in 25 μL total volume reactions, 
which contained 200nM of each probe and 300nM of each primer, and 40U of 
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recombinant ribonuclease inhibitorq. Cycling parameters were as follows: cDNA 
production at 42ºC for 30 min, hot start Taq polymerase activation at 95ºC for 2 minutes, 
followed by 45 cycles of denaturation at 95ºC for 10 seconds, annealing at 60ºC for 40 
seconds, and extension at 72ºC for 30 seconds.  
To standardize the total amount of RNA in each reaction, mRNA expression of the 
housekeeping gene glyceraldehyde 3-phosphate dehydrogenase was used to allow 
relative quantitation of the viral RNA by the comparative threshold cycle (2-ΔΔCt) method 
[119]. 
TCID50 assay 
Forty-eight hours after infection with FCoV, 500 µL of tissue culture medium was 
collected from each well and stored at -80°C prior to viral titration with the TCID50 assay.  
In brief, samples of culture medium were serially diluted 10-fold with DMEM. Diluted virus 
suspensions were added to monolayers CRFK cells cultured in 96-well plates (6 
wells/dilution). Wells were monitored for cytopathic effects such as cells rounding, 
clumping and detachment at 72 hours after infection by means of an inverted phase-
contrast microscope. The TCID50 endpoint values were calculated according to the 
method of Reed and Muench [124]. 
Cell viability assay 
A cell proliferation assayp was performed to determine any potential cellular toxic 
effects resulting from transfection of the CRFK cells. The CRFK cells were propagated to 
80% confluency in a 96-well tissue culture plate. The CRFK cells were transfected with 
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each of the 3 siRNAs combinations or underwent mock transfection.  After 24 hours, cell 
viability reagent was added to each well. A colored product produced by metabolically 
active cells was detected by a microplate readerq that measured absorbance at 490 nm. 
The quantity of this colored product was directly proportional to the number of living cells 
in the sample. The samples were evaluated and compared with findings for untreated 
CRFK cell control wells. Each sample was tested in triplicate, and the experiment was 
done twice. 
Resistance of FCoV to siRNA combination treatment 
To investigate the ability of the treated FCoV to tolerate siRNA treatment without 
developing drug resistance via mutation in the target region, extracellular progeny virus 
from siRNA combination 3 (siRNA-L, siRNA-U, and siRNA-N combination) transfected, 
FIPV WSU 79-1146-infected cells was harvested. This harvested virus was used to infect 
CRFK cells 24 hours after being transfected with siRNA combination 3. Forty-eight hours 
after viral infection, siRNA treated as well as control CRFK cells were treated with a 
permeabilization reagent j (according to manufacturer’s protocol) to assess virus protein 
expression by flow cytometryl as described earlier. Experimental controls included 1) cells 
transfected with siRNA combination 3, FIPV WSU 79-1146 (stock virus) infected cells 2) 
cells transfected with negative control non-targeting siRNA-treated, FCoV-infected cells 
and 3) uninfected cells. Inhibition of protein expression of siRNA combination 3 treated 
progeny virus was compared to that of siRNA treated stock virus FIPV WSU 79-1146. 
Further, to confirm the sequence identity between the designed siRNA and the 
progeny virus nucleic acid as well as the stock virus nucleic acid, the viral nucleic acid 
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was extracted from the harvested extracellular virus and the stock virus as mentioned 
previously.  Three Primer sets were designed (using Primer3 software) using the 
published sequence of FIPV WSU 79-1146 to amplify ~150 to 220 nucleotides each of 
the viral leader sequence, 3′ untranslated region and nucleocapsid gene (Table 3.1). Each 
of these amplicons includes the siRNA complementary region and was used to compare 
the sequence identity using BlastN on the NCBI website.  
Statistical analysis 
All statistical testsr were done with an ANOVA to compare any significant 
differences between the mean values of treated samples and the negative control 
nontargeting siRNA-treated, FCoV-infected samples. The ANOVA assumption of 
normality was tested with the Shapiro-Wilk statistic. When this assumption was not met, 
a logarithmic transformation or ANOVA on rank transformation of the data was done, and 
the Levene test was used to test the ANOVA equality of variance assumption. Bonferroni 
adjustment was used to minimize the type I error rate.  The Fisher least significant 
difference method of mean separation was used to determine which means differed 
significantly. A value of P =0.05 was considered significant. 
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Table 3.1— Design of the primers that were used to amplify ~150-220 nucleotides each 
of the viral leader sequence, 3′ UTR region and nucleocapsid gene. Nucleotide 
sequences and locations are based on GenBank accession No. DQ010921. 
 
primer Oligonucleotide sequence 
Amplimer 
size 
(nucleotides) 
Nucleotide 
sequence location 
Leader region    
Forward 5’– AAAGTGAGTGTAGCGTGGCTAT –3’ 
209 
12-33 
Reverse 5’– TTACCAAACAGGGACGAAC –3’ 221-206 
UTR region    
Forward 5’– CGCGCTGYCTACTCTTGTA –3’ 
156 
28898-28916 
Reverse 5’– CTCTTCCATTGTTGGCTCGT –3’ 29054-29035 
Nucleocapsid    
Forward 5’– GCCGTGCTTSAAAAATTAGG –3’ 
221 
27364-27383 
Reverse 5’– GTTTGGCAGCGTTACCATTG –3’ 27585-27567 
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Results 
Effect of siRNA combinations on the expression of FCoV proteins 
Flow cytometric evaluation of viral protein expression in cells transfected with 
siRNA combinations revealed a significant decrease in protein expression following 
infection with FIPV WSU 79-1146 (p< 0.001) and FECV WSU 79-1683 (p= 0.0046) as 
compared with the negative control sample. Protein expression of the FIPV WSU 79-1146 
strain was decreased by 91 ± 6%, 91 ± 2%, and 90 ± 5% after treating CRFK cells with 
siRNA combination1 (UTR + L), combination 2 (UTR + NC), and combination 3 (UTR + L 
+ NC), respectively, as compared with the negative control sample (Fig. 3.1). The protein 
expression of the FECV WSU 79-1683 strain was decreased by 95 ± 1%, 94 ± 1%, and 
95 ± 1% after treating CRFK cells with siRNA combinations (1), (2), and (3), respectively, 
as compared with the negative control sample (Fig.3.2). 
Inhibition of viral genomic RNA by siRNA combinations 
The 3 siRNA combinations showed significant inhibition of both strains of FCoV 
genomic RNA (p < 0.001). The 3 combinations resulted in ~ 97 ± 1.4%reduction in FIPV 
WSU 79-1146 genomic RNA (Fig.3.3) and 96 ± 4%, 92 ± 9%, and 93 ± 7% reductions in 
FECV WSU 79-1683 genomic RNA after treating CRFK cells with siRNA combinations 
(1), (2), and (3), respectively, as compared with the negative control sample (Fig. 3.4). 
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 Figure 3.1—Results of flow cytometric analysis (no. of events/channel vs fluorescence 
intensity [logarithm base 10]) illustrating the effect of siRNA combinations on the 
expression of FIPV WSU 79-1146 protein in virus-infected CRFK cells. The CRFK cells 
were transfected with 1 of 3 of siRNA combinations (concentration, 100nM [orange]) or a 
negative control siRNA (purple) 24 hours prior to viral infection (MOI, 0.1). At 48 hours 
after viral infection, CRFK cells were stained with labeled anti–FCoV polyclonal antibody 
following a standard protocol, and cell fluorescence was assessed by flow cytometry. The 
tested siRNA combinations included siRNA-L (targeting the FCoV leader region) and 
siRNA-U (targeting the 3′ untranslated region [A]); siRNA-L and siRNA-N (targeting the 
nucleocapsid gene [B]); and siRNA-L, siRNA-U, and siRNA-N (C).  In each panel, the 
data represent the results of 1 of 2 independent experiments that yielded similar results; 
each sample was assessed in duplicate. 
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Figure 3.2—Results of flow cytometric analysis (no. of events/channel vs fluorescence 
intensity [logarithm base 10]) to illustrate the effect of siRNA combinations on the 
expression of FECV WSU 79-1683 protein in virus-infected CRFK cells. The CRFK cells 
were transfected with 1 of 3 of siRNA combinations (concentration, 100nM [orange]) or 
a negative control nontargeting siRNA (green) 24 hours prior to viral infection (MOI, 
0.1). At 48 hours after viral infection, CRFK cells were stained with labeled anti–FCoV 
polyclonal antibody following a standard protocol, and cell fluorescence was assessed 
by flow cytometry. The tested siRNA combinations included siRNA-L (targeting the 
FCoV leader region) and siRNA-U (targeting the 3′ untranslated region [A]); siRNA-L 
and siRNA-N (targeting the nucleocapsid gene [B]); and siRNA-L, siRNA-U, and siRNA-
N (C).  In each panel, the data represent the results of 1 of 2 independent experiments 
that yielded similar results; each sample was assessed in duplicate. 
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Figure 3.3— Results of quantitative real-time RT-PCR to illustrate the effect of siRNA 
combinations on FIPV WSU 79-1146 genomic RNA replication in CRFK cells (the Y axis 
represents the relative viral genomic production %). The CRFK cells were transfected 
with 1 of 3 siRNA combinations (concentration, 100nM), or a negative control 
nontargeting siRNA 24 hours prior to viral infection (MOI, 0.1) or remained untreated. The 
tested siRNAs\ combinations included siRNA-L (targeting the FCoV leader region) and 
siRNA-U (targeting the 3′ untranslated region [C1]); siRNA-L and siRNA-N (targeting the 
nucleocapsid gene C2]); and siRNA-L, siRNA-U, and siRNA-N (C3). Forty-eight hours 
after viral infection, CRFK cells were collected and the nucleic acid was extracted to 
perform real-time RT-PCR. Each combination was tested in duplicate, and the data 
represent the mean ± SD of 2 independent experiments. 
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Figure 3.4— Results of quantitative real-time RT-PCR to illustrate the effect of siRNA 
combinations on FIPV WSU 79-1146 genomic RNA replication in CRFK cells (the Y axis 
represents the relative viral genomic production %). The CRFK cells were transfected 
with 1 of 3 siRNA combinations (concentration, 100nM), or a negative control 
nontargeting siRNA 24 hours prior to viral infection (MOI, 0.1) or remained untreated. The 
tested siRNA combinations included siRNA-L (targeting the FCoV leader region) and 
siRNA-U (targeting the 3′ untranslated region [C1]); siRNA-L and siRNA-N (targeting the 
nucleocapsid gene C2]); and siRNA-L, siRNA-U, and siRNA-N (C3). Forty-eight hours 
after viral infection, CRFK cells were collected and the nucleic acid was extracted to 
perform real-time RT-PCR. Each combination was tested in duplicate, and the data 
represent the mean ± SD of 2 independent experiments. 
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Effect of siRNA combinations on the yield of progeny virus (extracellular virus titer) 
The 3 siRNA combinations resulted in about a 100 fold reduction in the 
extracellular virus titer of both viral strains (p < 0.001), as compared with the negative 
control siRNA sample, which represented ~ 95% reduction in virus replication (Fig. 3.5 
and Fig. 3.6). To confirm that siRNAs were designed to specifically target FCoV, the titer 
of the extracellular virus from the FCoV-infected cells and the negative control non-
targeting siRNA, FCoV-infected cells were assessed with TCID50 assay.  There was no 
significant difference in the titers of the extracellular virus from FECV WSU 79-1683  nor 
FIPV WSU 79-1146 infected cells, as compared with the negative control non-targeting 
siRNA, FCoV- infected cells (p = 0.211 and p = 0.5055, respectively). This showed that 
the transfection and/or non-targeting siRNA does not have a nonspecific inhibitory effect 
on FCoV and confirms the specificity of the designed siRNAs.  
Effect of siRNA transfection on cell viability 
Microscopic examination (by means of an inverted phase-contrast microscope) 
revealed that the number of viable cells among CRFK cells transfected with each of the 
3 siRNA combinations was comparable to the number of viable cells among untreated 
CRFK cells, as well as the numbers of viable cells among cells transfected with negative 
non-targeting siRNA and cells that underwent mock transfection. Furthermore, a cell 
proliferation assay was used to investigate any potential cytotoxic effect of the siRNA 
combinations. Assay results indicated that the 3 siRNA combinations and the transfection 
reagent had no significant effect on cell viability, compared with viability of untreated 
CRFK cells. The mean ± SD optical density of the untreated cells was 0.9920 ± 0.017 
absorbance, which was not significantly (P = 0.1) different from the mean optical density  
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Figure 3.5— Results of a TCID50 assay to illustrate the effect of siRNA combinations on 
the yield of FIPV WSU 79-1146 progeny virus in CRFK cells. The CRFK cells were 
transfected with 1 of 3 siRNA combinations (concentration, 100nM), or a negative 
control non-targeting siRNA 24 hours prior to viral infection (MOI, 0.1) or remained 
untreated. The tested siRNA combinations included siRNA-L (targeting the FCoV leader 
region) and siRNA-U (targeting the 3′ untranslated region [C1]); siRNA-L and siRNA-N 
(targeting the nucleocapsid gene C2]); and siRNA-L, siRNA-U, and siRNA-N (C3). 
Forty-eight hours after viral infection, a sample of cell culture supernatant was collected 
from each well for titration. Each combination was tested in duplicate, and the data 
represent the mean ± SD of 2 independent experiments. For cells treated with any of 
the 3 siRNA combinations, viral replication was significantly different from that in 
infected cells treated with the negative control non-targeting siRNA. There was no 
significant difference in extracellular virus titers for untreated cells infected with FIPV 
WSU 79-1146, compared with the infected cells treated with the negative control non-
targeting siRNA.   
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Figure 3.6—Results of a TCID50 assay to illustrate the effect of siRNA combinations on 
the yield of FECV WSU 79-1683 progeny virus in CRFK cells. The CRFK cells were 
transfected with 1 of 3 siRNA combinations (concentration, 100nM), or a negative 
control non-targeting siRNA 24 hours prior to viral infection (MOI, 0.1) or remained 
untreated. The tested siRNA combinations included siRNA-L (targeting the FCoV leader 
region) and siRNA-U (targeting the 3′ untranslated region [C1]); siRNA-L and siRNA-N 
(targeting the nucleocapsid gene C2]); and siRNA-L, siRNA-U, and siRNA-N (C3). 
Forty-eight hours after viral infection, a sample of cell culture supernatant was collected 
from each well for titration. Each combination was tested in duplicate, and the data 
represent the mean ± SD of 2 independent experiments. For cells treated with any of 
the 3 siRNA combinations, viral replication was significantly different from that in 
infected cells treated with the negative control non-targeting siRNA. There was no 
significant difference in extracellular virus titers for untreated cells infected and FECV 
WSU 79-1683, compared with the infected cells treated with the negative control non-
targeting siRNA.   
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of the mock-transfected cells (0.9353 ± 0.2 absorbance) or from the cells transfected with 
the siRNA-L and siRNA-U combination (0.9576 ± 0.02 absorbance), the siRNA-L and 
siRNA-N combination (1.0433 ± 0.049 absorbance), or the siRNA-L, siRNA-U, and 
siRNA-N combination (1.0636 ±  0.018 absorbance). 
Resistance of FCoV to siRNA combination treatment 
To determine the ability of treated FCoV strain to tolerate the siRNA treatment 
without developing mutation in the siRNA target region, we compared siRNA combination 
3 (siRNA-L, siRNA-U, and siRNA-N combination) inhibitory effect on the viral protein 
expression of; extracellular progeny virus (harvested from siRNA treated, FCoV infected 
cells) and FIPV WSU 79-1146 (stock virus) using flow cytometery. Flow cytometric 
evaluation of the viral protein expression showed 60.5± 5% and 65 ± 5%, inhibition in the 
viral protein expression of the extracellular progeny virus and FIPV WSU 79-1146 
respectively as compared with the negative control non-targeting siRNA, FIPV WSU 79-
1146- infected cells. This result revealed no significant difference in protein expression 
following infection of siRNA treated cells with either the extracellular progeny virus or 
FIPV WSU 79-1146 (p= 0.05) based on paired t-test analysis. Further, sequencing of the 
siRNAs target regions of both the progeny virus and FIPV WSU 79-1146 genome showed 
100% homology. 
Discussion 
Feline infectious peritonitis (FIP) is a progressive, fatal disease of cats that is 
characterized by a poor cell-mediated immune response and continued systemic virus 
replication, as well as an exaggerated humoral response to the virus. Currently, there is 
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no effective treatment for FIP. Our previous results (chapter 2) showed that individual 
siRNAs each targeting a single gene were able to inhibit FCoV replication in vitro.   The 
inhibitory effect of siRNA is stated to be increased by combining multiple siRNAs targeting 
either the same or different gene.  
In the present study, siRNA combinations that target highly conserved regions of 
FCoV coding and noncoding genes were able to inhibit virus gene expression and 
thereafter inhibit replication of the virus.  The 3 combinations of siRNAs that target 
different regions of the viral genome showed more effective inhibition on the viral 
replication of both FCoV strains than individual siRNAs as compared with the negative 
control non-targeting siRNA sample. Combinations of siRNAs targeting different regions 
led to a significant synergistic effect on viral inhibition compared to individual siRNA 
treatment [123]. Moreover, using combinations of siRNAs that target highly conserved 
regions has been reported to be able to reduce or prevent the development of escape 
mutants that could resist the inhibitory effect of the introduced siRNA. Nucleotide 
substitution occurs frequently in the FCoV genome, thus, reducing the probability of drug 
resistance development via mutation is very important to achieve an effective antiviral 
effect.  
 siRNA-L, which targets the FCoV leader sequence, was included in each of the 3 
combinations used in the present study because this region is highly conserved in FCoV 
and plays an important role in virus gene expression and replication [121]. Another siRNA 
used in combination was siRNA-U, which targets the 3′ UTR  noncoding region, which is 
highly conserved in FCoV and has an essential role in regulating the viral transcription 
and replication cycle.[93] Moreover, during virus replication, a 5 common leader 
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sequence and 3′ co-terminal nested set of sgRNAs are made [18]. Therefore, siRNA-L 
and siRNA-U target genomic RNAs and all the viral nested sgRNAs. The other siRNA 
used in tested combinations was siRNA-N, which targets the viral nucleocapsid gene.  
Viral nucleocapsid protein is a virion structural protein that protein plays an important role 
in the viral replication and proposed to be an interferon antagonist that likely plays a role 
in circumventing the innate immune response.  
Given the poor host or cell-mediated immune response associated with enhanced 
viral replication in cats with FIP, the effective reduction of viral replication by the siRNA 
combinations used in the present in vitro study may be useful in vivo; treatment of FIP-
affected cats with an siRNA combination may, in part, restore the host immune response 
and thereafter improve viral clearance. Reduction of viral replication with siRNA treatment 
could also reduce the likelihood of mutation and reduce the expansion of any virus 
population containing the mutation of importance in development of FIP. 
Interestingly, each siRNA  (25 mer) used in the present study was manufactured 
with an RNAi designer that provides siRNAs that have higher specificity for the intended 
target gene   and increased stability in serum and cell culture than standard siRNAs (21 
mer). This method of manufacture eliminates unwanted off-target effects [117]. Therefore, 
the siRNA combinations used in the present study can be directly applied in an in vivo 
study without the need for any chemical modification that may interfere with their targeting 
effect. In vivo delivery of these siRNA combinations to FIPV target cells (Monocytes and 
macrophages) could successfully inhibit the viral replication and limit the disease. 
Unfortunately, systemic delivery of siRNA is considered to be a big challenge that face 
the clinical application of this technology. However, recently there are various delivery 
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systems, successfully delivered siRNA to the monocytes and macrophages, suggesting 
a promising clinical application of RNAi in treating FIP [125, 126]. 
 To our knowledge, this is the first study to investigate the effectiveness of siRNA 
combinations to inhibit FCoV replication. Our siRNAs combinations markedly inhibited 
FCoV genomic RNA, FCoV protein and FCoV replication in vitro. These results indicate 
that FCoV replication can be specifically and significantly inhibited with siRNAs 
combinations targeting different highly conserved coding and regulatory noncoding 
regions of the viral genome/mRNA. Since the exact genetic changes that led to the 
mutation of the non-virulent FECV to the virulent FIPV is still controversial, it was very 
important to designed siRNAs that target FCoVs of different genetic background and 
therefore, can inhibit the replication of any viral strains circulating in the field. These siRNA 
combinations seemed to be a promising tool to prevent and/or treat FIP. Inhibition of 
FECV replication in seropositive cats and chronic shedders using siRNA technology can 
help these cats to clear the virus and prevent the possibility of the mutation of FECV to 
FIPV and the development of this fatal disease. 
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Chapter 4 
General Summary 
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Feline coronavirus (FCoV) is enveloped virus with a large, capped, polyadenylated 
RNA genome of about 30 Kb nucleotides and belongs to Genus alphacoronavirus, in the 
family Coronaviridae. FCoV genome includes 11 putative ORFs; two large ORFs encode 
viral non-structural replicase proteins; structural ORFs that encode spike, envelope, 
membrane, and nucleocapsid proteins and five ORFs encode the nonstructural proteins 
3a, 3b, 3c, 7a, and 7b [9].  
FCoV causes a mild or often subclinical enteric infection, especially in kittens. 
However, in some cats it can cause fatal systemic disease known as feline infectious 
peritonitis (FIP). FIP can manifest in two forms; 1) the wet form, which is characterized by 
fibrinous, granulomatous serositis, with protein-rich effusions in the body cavities of 
affected cats and 2) the dry form, which is characterized by granulomatous inflammatory 
lesions of several organs especially, liver, kidney, spleen, CNS, and eyes [6]. It has been 
proposed that a mutant FCoV which is capable of infecting and replicating in the 
monocytes and macrophages is responsible for the development of FIP[8]. 
To date, treatment of FIP has been ineffective, with affected cats progressing 
inevitably to death. Because of the immune-mediated component of the disease, 
treatments directed at enhancing the cell-mediated response (eg, interferon) or 
suppressing the humoral response (eg, corticosteroids and cyclophosphamide) have 
been used with little or no success [37]. Recently, polyprenyl, an agent that is postulated 
to enhance T lymphocyte activity, has been used with some success in cats with the dry 
form of FIP but not in cats with the common effusive form of the disease. These results 
reflect the importance of limiting the viral load (replication); viral spread and replication is 
greater with the wet form than with the dry form [36]. It seems that the high viral burden 
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associated with the wet form of the disease interferes with the ability of the host immune 
response to restore its normal physiological function. Reducing virus replication in 
infected cats as well as enhancing the host immune response could improve the ability of 
an infected animal to control development of disease. 
Recently, RNAi mechanism has been studied as a therapeutic tool for various 
mammalian infections including viral infection [5, 72, 127]. RNAi is a highly conserved 
biological process found in plants and animal cells. This biological process can be 
induced artificially via the introduction of synthetic, short interfering RNA (siRNA). 
Subsequently, this siRNA is incorporated into RNA induced silencing complex (RISC), an 
enzyme complex with RNAase and helicase activity [4]. The RISC guides the introduced 
siRNA to the target complementary sequences and results in sequence specific silencing 
of the gene of interest. In the present study, we found that individual siRNAs and siRNAs 
combinations that target highly conserved regions of FCoV coding and noncoding genes 
are able to inhibit virus gene expression and thereafter inhibit replication of the virus.  
FCoV is considered a good target for siRNA treatment, because the viral full-length 
genome contains nearly all the sequences found in any of the sgRNAs. Thus, siRNA that 
targets the sgRNAs will target the full-length genomic RNA too.  The siRNAs used in the 
present study (siRNA-L, siRNA-U, siRNA-N, siRNA-M, and siRNA-R) each targeted a 
single gene and had a variable inhibitory effect on FCoV replication in vitro. Further, 
multiple combinations of the most effective individual siRNAs were examined. Inhibition 
of the viral replication by each combination was more effective than that achieved by the 
individual siRNAs, compared with findings for the negative control non-targeting siRNA 
FCoV-infected sample. Combinations of siRNAs targeting different regions showed a 
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significant synergistic effect on viral inhibition, compared to results of treatment with 
individual siRNAs. Additionally, in our study the cell proliferation assay revealed that the 
siRNA combinations produced no cytotoxic effects in the transfected cells.   
Because FCoV has a high mutation rate, the probability that the virus may evade 
siRNA targeting through viral mutations is considered a challenge to the design of 
siRNAs. To overcome this limitation, siRNAs that target highly conserved regions of 
essential viral genes as well as combinations of these siRNAs were used to prevent or 
reduce development of viral escape mutants.  Mutation is less likely to occur in the highly 
conserved regions that have an important role during the viral replication cycle, because 
such mutations might have a deleterious effect on the virus [120, 128]. Furthermore, in 
the present study, the siRNA targets chosen had ~100% homology with FCoV sequences 
deposited in GenBank. This level of homology reveals a selective potential against 
mutation during the evolution of the virus. An additional benefit of targeting highly 
conserved regions of the viral genome is to overcome the genetic diversity problem 
among FCoVs, which is considered an additional challenge to designing specific siRNAs. 
Thus, siRNAs can be designed to recognize and target various strains of FCoVs that 
circulate in the field.  Given the poor host or cell-mediated immune response associated 
with enhanced viral replication in cats with FIP, the effective reduction of viral replication 
by the siRNA combinations used in the present in vitro study may be useful in vivo; 
treatment of FIP-affected cats with an siRNA combination may, in part, restore the host 
immune response and thereafter improve viral clearance. Reduction of viral replication 
with siRNA treatment could also reduce the likelihood of mutation and reduce the 
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expansion of any virus population containing the mutation of importance in development 
of FIP. 
Unlike a previous study [129] that investigated the inhibitory effect of individual 
siRNAs that each targeted a single gene, the present study investigated the effectiveness 
of siRNA combinations that targeted 2 or 3 regions of the viral genome on in vitro inhibition 
of FCoV replication. The siRNA combinations markedly inhibited FCoV genomic RNA, 
FCoV protein, and FCoV replication. These results indicated that FCoV replication can 
be specifically and significantly inhibited with siRNA combinations that target different 
highly conserved coding and regulatory noncoding regions of the viral genome or mRNA, 
suggesting a potential therapeutic application of RNA interference in the treatment of cats 
with FIP. Development of agents such as siRNAs for treatment of FIP is a potential means 
to combat this highly fatal viral disease that is now considered to be the primary infectious 
cause of death in young cats [1]. With improvements in siRNA design and delivery 
methods, RNA interference might be an effective treatment option for such a life-limiting 
viral infection. 
 
a. Crandell-Rees feline kidney cell line, American Type Culture Collection, Manassas, Va. 
b. DMEM:F-12, Lonza, Walkersville, MD. 
c. Fetal Bovine serum, Atlanta Biologicals, Lawrenceville, Ga. 
d. FIPV WSU 79-1146, American Type Culture Collection, Manassas, Va. 
e. FECV WSU 79-1683, American Type Culture Collection, Manassas, Va. 
f. Stealth siRNA, Invitrogen, Carlsbad, Calif. 
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g. Block-iT RNAi designer, Invitrogen, Carlsbad, Calif. 
h. Lipofectamine 2000, Invitrogen, Carlsbad, Calif. 
i. Fluorescently labeled siRNA, Invitrogen, Carlsbad, Calif. 
j. IntraPrep permeabilization reagent, Immunotech, Marseille, France. 
k. Polyclonal Ab, VMRD, Pullman, Wash. 
l. Flow cytometr, Epics XL, Beckman Coulter, Fullerton, Calif. 
m. RNeasy Plus Mini Kit, Qiagen, Valencia, Calif. 
n. QIAshredder, Qiagen, Valencia, Calif. 
o. Superscript III Platinum One-Step qRT-PCR Kit, Invitrogen, Carlsbad, Calif. 
p. SmartCycler II, Cepheid, Sunnyvale, Calif. 
q. Qia shredder, Invitrogen, Carlsbad, Calif. 
r. CellTiter 96 AQueous One Solution Cell Proliferation Assay, Promega, Madison, Wis. 
s.  ELx800 Universal Microplate Reader, Bio-Tek Inc, Winooski, Vermont.  
t. SAS, version 9.3, SAS Institute, Cary, NC. 
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